- Condition: Hypergastrinaemia
Interventions: Drug: YF476; Drug: Placebo
Sponsors: Trio Medicines Ltd.; Trio Medicines Ltd.; James Black Foundation
Completed - verified May 2012 - Condition: Hypergastrinaemia
Interventions: Drug: YF476; Drug: Placebo
Sponsors: Trio Medicines Ltd.; Trio Medicines Ltd.; James Black Foundation
Completed - verified May 2012 - Condition: Basal Cell Carcinoma
Intervention: Other: OCT
Sponsors: Maidstone & Tunbridge Wells NHS Trust; Maidstone & Tunbridge Wells NHS Trust
Not yet recruiting - verified May 2012 - Conditions: Heart Failure; Endothelium
Intervention: Drug: Urocortin 2, Urocortin 3 and Substance P
Sponsors: University of Edinburgh; University of Edinburgh; NHS Lothian
Not yet recruiting - verified May 2012 - Condition: Reflux Oesophagitis
Interventions: Drug: YF476; Drug: Omeprazole
Sponsors: Trio Medicines Ltd.; Trio Medicines Ltd.; Ferring Pharmaceuticals
Completed - verified May 2012 - Condition: Reflux Oesophagitis
Intervention: Drug: YF476
Sponsors: Trio Medicines Ltd.; Trio Medicines Ltd.; Ferring Pharmaceuticals
Completed - verified May 2012 - Conditions: Anxiety; Depression
Interventions: Behavioral: Individual Career Management (ICM); Behavioral: Standard Care
Sponsors: South London and Maudsley NHS Foundation Trust; South London and Maudsley NHS Foundation Trust
Recruiting - verified May 2012 - Condition: Idiopathic Pulmonary Arterial Hypertension
Interventions: Drug: (Pyr1)apelin-13; Drug: Saline
Sponsors: Imperial College London; Imperial College London
Recruiting - verified April 2012 - Condition: Influenza, Human
Intervention: Biological: CSL Influenza Vaccine
Sponsors: CSL Limited; CSL Limited
Active, not recruiting - verified May 2012 - Condition: Obesity
Interventions: Other: Breakfast Study; Other: fMRI Study
Sponsors: University of Aberdeen; University of Aberdeen; European Union
Recruiting - verified May 2012 - Condition: Healthy Volunteers
Interventions: Drug: LY2140023 Monohydrate (Reference); Drug: LY2140023 Monohydrate (Test - Low); Drug: LY2140023 Monohydrate (Test - Medium); Drug: LY2140023 Monohydrate (Test - High)
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Healthy
Interventions: Dietary Supplement: Dietary supplement of iron; Drug: Ferrous sulphate
Sponsors: Imperial College London; Imperial College London
Active, not recruiting - verified April 2012 - Condition: Patients Requiring Forefoot Surgery
Interventions: Device: Darco shoe; Device: Podalux shoe; Device: Standard dressing shoe
Sponsors: Sheffield Teaching Hospitals NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation Trust
Not yet recruiting - verified May 2012 - Condition: Healthy
Interventions: Dietary Supplement: 2 portions of fruit and vegetables per day; Dietary Supplement: 5 portions of fruit and vegetables per day; Dietary Supplement: 8 portions of fruit and vegetables per day
Sponsors: Queen's University, Belfast; Queen's University, Belfast
Recruiting - verified May 2012 - Condition: Cardiovascular Disease
Intervention: Dietary Supplement: High/ Low Epicatechin Apples/ Apple Extract/ Granules
Sponsors: Queen's University, Belfast; Queen's University, Belfast
Recruiting - verified April 2012 - Conditions: Gut Microbiota; Immune Function
Interventions: Dietary Supplement: Synbiotic; Dietary Supplement: Placebo; Dietary Supplement: Prebiotic; Dietary Supplement: Probiotic
Sponsors: University of Reading; University of Reading; Danisco
Completed - verified April 2012 - Condition: Cough
Interventions: Drug: GSK2339345 (Inhaled) Single Dose; Other: Placebo (Inhaled) Single Dose; Drug: GSK2339345 (Inhaled) Repeat Dose; Other: Placebo (Inhaled) Repeat Dose
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Cardiovascular Function
Intervention: Biological: Typhoid vaccine
Sponsors: Queen Mary University of London; Queen Mary University of London
Recruiting - verified April 2012 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Cervical Cancer; Endometrial Cancer; Esophageal Cancer; Fallopian Tube Cancer; Gastric Cancer; Ovarian Cancer; Sarcoma; Vaginal Cancer; Vulvar Cancer
Intervention:
Sponsors: Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of Surrey
Recruiting - verified April 2012 - Condition: Cardiovascular Disease
Intervention:
Sponsors: Queen Mary University of London; Queen Mary University of London; King's College London
Not yet recruiting - verified April 2012 - Conditions: Meningitis; Meningococcal Disease; Septicaemia
Interventions: Biological: MenACWY-CRM conjugate vaccine (Menveo, Novartis); Biological: MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis); Biological: MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis); Biological: 1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)
Sponsors: University of Oxford; University of Oxford
Not yet recruiting - verified May 2012 - Condition: Insufficient Information
Interventions: Drug: sibutramine; Other: sibutramine placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified May 2012 - Condition: Lip Volume Enhancement
Interventions: Device: Juvéderm® Volbella with Lidocaine; Device: Restylane-L®
Sponsors: Allergan Medical; Allergan Medical
Recruiting - verified April 2012 - Condition: Determination of Pregnancy Status
Intervention: Other: Clearblue Advanced
Sponsors: SPD Development Company Limited; SPD Development Company Limited
Recruiting - verified April 2012 - Condition: Pregnancy
Intervention: Other: Ovulation predictions products
Sponsors: SPD Development Company Limited; SPD Development Company Limited
Recruiting - verified January 2012 - Conditions: Health Behavior; Physical Activity
Interventions: Behavioral: Non-cash incentives; Behavioral: Self-monitoring physical activity levels
Sponsors: Queen's University, Belfast; Queen's University, Belfast
Completed - verified April 2012 - Condition: Obesity
Intervention: Other: Dietary Fiber
Sponsors: National Starch LLC; National Starch LLC
Recruiting - verified April 2012 - Condition: Healthy
Interventions: Drug: 600 mg ceftaroline fosamil in 50 ml infusion volume; Drug: Placebo in 50 ml infusion volume; Drug: 600 ceftaroline fosamil in 250 ml infusion volume; Drug: Placebo in 250 ml infusion volume; Drug: 600 mg ceftaroline in 100 ml infusion volume; Drug: Placebo in 100 ml infusion volume
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2012 - Condition: Mildly Hypercholesterolemic Subjects
Interventions: Other: 1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 10 mg of policosanols per unit; Other: 2- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 20 mg of policosanols per unit; Other: 3- Low fat drinkable fermented dairy product with 1.6g of plant sterol (as free equivalent) but without policosanols (Active control)
Sponsors: Danone Research; Danone Research; GUILDFORD CLINICAL PHARMACOLOGY UNIT LTD. (GCPL)
Completed - verified April 2012 - Condition: Respiratory Disorders
Interventions: Drug: GSK1995057; Procedure: bronchoalveolar lavage; Drug: LPS; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Emergency Contraception
Interventions: Drug: Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon); Drug: placebo + ethinylestradiol/levonorgestrel
Sponsors: HRA Pharma; HRA Pharma
Recruiting - verified March 2012 - Condition: Emergency Contraception
Intervention: Drug: ellaOne
Sponsors: HRA Pharma; HRA Pharma
Recruiting - verified March 2012 - Condition: TTR-mediated Amyloidosis
Interventions: Drug: ALN-TTR02; Drug: Sterile Normal Saline (0.9% NaCl)
Sponsors: Alnylam Pharmaceuticals; Alnylam Pharmaceuticals
Recruiting - verified March 2012 - Condition: Healthy Volunteers
Intervention: Other: sedimenting meal
Sponsors: Institute of Food Research; Institute of Food Research; Norfolk and Norwich University Hospitals NHS Foundation Trust; Top Institute Food and Nutrition
Completed - verified May 2012 - Condition: Healthy
Interventions: Drug: AZD8848; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2012 - Condition: Influenza Virus
Interventions: Drug: VX-787; Drug: VX-787
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Not yet recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: Intravenous (IV) single dose; Drug: Subcutaneous (SC) single dose
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Condition: Japanese Encephalitis
Intervention: Biological: IXIARO
Sponsors: Intercell AG; Intercell AG
Not yet recruiting - verified April 2012 - Conditions: Haemophilia; Haemophilia A; Haemophilia B; Healthy
Interventions: Drug: NNC172-2021; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified May 2012 - Conditions: Neisseria Meningitidis; Bacterial Infections; Virus Diseases
Interventions: Biological: V419 (PR5I); Biological: Prevenar 13; Biological: NeisVac-C; Biological: MENJUGATE; Biological: MENITORIX; Biological: M-M-RVAXPRO
Sponsors: Sanofi Pasteur MSD; Sanofi Pasteur MSD
Recruiting - verified May 2012 - Conditions: Enteral Feeding; Nasogastric Feeding; Diarrhoea
Interventions: Dietary Supplement: NG bolus feeding over 5 min; Dietary Supplement: Continuous NG feeding over 4 h
Sponsors: University of Nottingham; University of Nottingham
Recruiting - verified March 2012 - Condition: Healthy Volunteers
Interventions: Drug: LY3016859 IV; Drug: Placebo IV; Drug: LY3016859 SC; Drug: Placebo SC
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Conditions: Gut Microbiota; Bowel Function; Immune Function; Plasma Lipids
Interventions: Dietary Supplement: Prebiotic; Dietary Supplement: Bi-07; Dietary Supplement: Synbiotic; Dietary Supplement: Placebo
Sponsors: University of Reading; University of Reading; Danisco
Completed - verified March 2012 - Condition: Chronic Kidney Disease
Intervention: Other: OxSalt care bundle
Sponsors: University of Oxford; University of Oxford; British Renal Society
Not yet recruiting - verified May 2012 - Condition: Aggression
Interventions: Dietary Supplement: Placebo; Dietary Supplement: Multi-vitamin/mineral; Dietary Supplement: Docosahexaenoic acid; Dietary Supplement: DHA plus vitamins/minerals
Sponsors: Swansea University; Swansea University
Completed - verified March 2012 - Conditions: Obstructive Sleep Apnoea; Obesity
Intervention: Behavioral: Combined lifestyle intervention
Sponsors: Sheffield Teaching Hospitals NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation Trust; Sheffield Hallam University
Completed - verified March 2012 - Conditions: Use of Video Education; Colorectal Surgery
Interventions: Procedure: The study group will get a video and leaflet on enhanced recovery; Procedure: The control group will receive a leaflet only
Sponsors: Ihedioha, Ugo, M.D.; Ihedioha, Ugo, M.D.
Completed - verified March 2012 - Condition: Reflux Oesophagitis
Intervention: Drug: YF476
Sponsors: Trio Medicines Ltd.; Trio Medicines Ltd.; Ferring Pharmaceuticals
Completed - verified February 2012 - Condition: Reflux Oesophagitis
Interventions: Drug: YF476; Drug: Ranitidine
Sponsors: Trio Medicines Ltd.; Trio Medicines Ltd.; Ferring Pharmaceuticals
Completed - verified February 2012 - Condition: Healthy Adult Subjects
Interventions: Drug: ONO-4053; Drug: Placebo
Sponsors: Ono Pharmaceutical Co. Ltd; Ono Pharmaceutical Co. Ltd
Recruiting - verified March 2012 - Conditions: No Condition; Brain GABA-B Function
Interventions: Drug: Baclofen 10mg; Drug: Baclofen 60mg; Drug: placebo
Sponsors: Imperial College London; Imperial College London; Medical Research Council
Not yet recruiting - verified March 2012 - Condition: Irritable Bowel Syndrome
Intervention:
Sponsors: University of Nottingham; University of Nottingham
Recruiting - verified February 2012 - Condition: Venus Leg Ulcers
Interventions: Device: Promogran; Device: Coban 2 layer
Sponsors: Systagenix Wound Management; Systagenix Wound Management
Not yet recruiting - verified February 2012 - Conditions: Glycemic Index; Glycemic Response
Interventions: Other: Dietary Intervention; Other: Dietary Intervention; Other: Dietary Intervention
Sponsors: Kraft Foods; Kraft Foods; Reading Scientific Services Limited (RSSL)
Recruiting - verified February 2012 - Condition: Central Nervous System
Interventions: Drug: alcohol + placebo; Drug: alcohol + perampanel; Drug: perampanel + alcohol; Drug: placebo + alcohol
Sponsors: Eisai Inc.; Eisai Limited
Completed - verified January 2012 - Condition: Retinal Diseases
Interventions: Drug: GW824575; Drug: GW824575 matched-placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012 - Condition: Dietary Modification
Interventions: Behavioral: Level 1 Dietary Intake; Behavioral: Level 2: Dietary Intake + Phenotype; Behavioral: Level 3 Dietary + Phenotype + Genotype; Behavioral: Level 0 Control Group
Sponsors: Newcastle University; Newcastle University; University College Dublin; Maastricht University; University of Oslo; University of Navarra; Harokopio University; University of Reading; National Food and Nutrition InstitutE; Technische Universität München; University of Newcastle Upon-Tyne
Not yet recruiting - verified February 2012 - Condition: Healthy Volunteers
Interventions: Drug: LY2979165; Drug: LY2140023; Other: Placebo; Other: Ketamine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Obesity
Intervention:
Sponsors: Imperial College London; Imperial College London; Medical Research Council
Recruiting - verified February 2012 - Condition: Cerebral Blood Flow
Interventions: Dietary Supplement: Berry drink; Dietary Supplement: Control
Sponsors: Northumbria University; Northumbria University; The New Zealand Institute for Plant and Food Research
Recruiting - verified February 2012 - Condition: Idiopathic Thrombocytopenic Purpura
Interventions: Drug: 10-mg dose of E5501 2G tablet; Drug: 10-mg dose of E5501 cyclodextrin oral solution; Drug: 10-mg dose of E5501-P21% powder; Drug: 10-mg dose of E5501 lipid-based oral
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified March 2012 - Condition: Cardiovascular Disease Risk Reduction
Interventions: Dietary Supplement: Flavanone - supplement; Other: Flavanone - food; Other: Flavanone - placebo; Dietary Supplement: Isoflavone - supplement; Other: Isoflavone - food; Other: Isoflavone - placebo; Dietary Supplement: Isoflavone - metabolite supplement; Dietary Supplement: Flavan-3-ol - supplement; Other: Flavan-3-ol - food; Other: Flavan-3-ol - placebo; Dietary Supplement: Anthocyanin - supplement; Other: Anthocyanin - food; Other: Anthocyanin - placebo
Sponsors: University of East Anglia; University of East Anglia
Not yet recruiting - verified February 2012 - Condition: Obesity
Intervention: Other: Study visit procedures
Sponsors: Sheffield Teaching Hospitals NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation Trust; NIHR Biomedical Research Unit for Musculoskeletal Disease
Recruiting - verified February 2012 - Condition: Sleep
Interventions: Dietary Supplement: Cherry juice; Dietary Supplement: Fruit juice cordial
Sponsors: Northumbria University; Northumbria University; University of Surrey
Completed - verified February 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Placebo Moxifloxacin; Drug: Moxifloxacin; Drug: GSK573719/Vilanterol 125/25mcg; Drug: GSK573719; Drug: GSK573719/Vilanterol 500/100mcg; Drug: Placebo DPI
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Conditions: Diabetes; Healthy
Interventions: Drug: biphasic insulin aspart 70; Drug: biphasic insulin aspart 70; Drug: biphasic insulin aspart 50
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012 - Conditions: Chronic Obstructive Pulmonary Disease; Asthma; Healthy; Chronic Cough; Smokers
Interventions: Other: Cough challenge test; Other: 24 hour ambulatory cough recording; Other: Cough quality of life questionnaire
Sponsors: University Hospital of South Manchester NHS Foundation Trust; University Hospital of South Manchester NHS Foundation Trust
Completed - verified April 2012 - Condition: Cardiovascular Disease
Interventions: Dietary Supplement: High saturated fat meal; Dietary Supplement: Saturated fatty acids and fish oil meal; Dietary Supplement: High unsaturated fat meal
Sponsors: University of Reading; University of Reading; Unilever R&D
Completed - verified January 2012 - Condition: Asthma
Intervention: Drug: inhaled steroid
Sponsors: Belfast Health and Social Care Trust; Liam Heaney; Northern Ireland Chest Heart & Stroke
Recruiting - verified February 2012 - Condition: Healthy Volunteers
Interventions: Drug: TMC435 150 mg capsule; Drug: TMC435 150 mg oral suspension (20 mg/mL); Drug: TMC435 150 mg oral solution (10 mg/mL); Drug: TMC435 150 mg capsule concept K; Drug: TMC435 150 mg capsule concept L
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Peripheral Bone Density
Intervention: Procedure: XtremeCT
Sponsors: Sheffield Teaching Hospitals NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation Trust
Active, not recruiting - verified February 2012 - Conditions: Infection of Total Hip Joint Prosthesis; Implants
Intervention:
Sponsors: University of East Anglia; University of East Anglia; Depuy, Inc.
Recruiting - verified February 2012 - Condition: Mood
Interventions: Dietary Supplement: 5-Hydroxytryptophan; Dietary Supplement: Pharmaceutical grade silica
Sponsors: Northumbria University; Northumbria University
Completed - verified January 2012 - Condition: Acute Lung Injury
Intervention: Other: Microdose of NAP
Sponsors: University of Edinburgh; University of Edinburgh; Medical Research Council
Not yet recruiting - verified January 2012 - Condition: Huntington's Disease
Interventions: Drug: SEN0014196; Drug: SEN0014196; Drug: SEN0014196; Drug: SEN0014196; Drug: SEN0014196; Drug: SEN0014196; Drug: SEN0014196; Drug: SEN0014196; Drug: SEN0014196; Drug: SEN0014196; Drug: SEN0014196
Sponsors: Siena Biotech S.p.A.; Siena Biotech S.p.A.
Completed - verified January 2012 - Condition: In-plane Ultrasound Guided Needling Training
Intervention:
Sponsors: University of Aberdeen; University of Aberdeen
Recruiting - verified April 2012 - Conditions: Iron Deficiency; Anaemia
Interventions: Dietary Supplement: alginate beads containing ferrous gluconate; Dietary Supplement: ferrous gluconate in a capsule; Dietary Supplement: ferrous gluconate in a capsule in presence of calcium; Dietary Supplement: alginate beads with ferrous gluconate in presence of calcium
Sponsors: University of East Anglia; University of East Anglia; Institute of Food Research
Recruiting - verified March 2012 - Conditions: Diabetes; Healthy
Interventions: Drug: NNC 90-1170; Drug: placebo; Drug: NNC 90-1170; Drug: NNC 90-1170; Drug: insulin human; Drug: insulin human; Drug: NNC 90-1170
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012 - Condition: Cerebral Vasculature
Intervention: Other: cocoa
Sponsors: NHS Greater Glasgow and Clyde; NHS Greater Glasgow and Clyde; University of Glasgow
Not yet recruiting - verified January 2012 - Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy
Interventions: Drug: NNC 90-1170; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012 - Conditions: Diabetes; Healthy
Interventions: Drug: NNC 90-1170; Drug: NNC 90-1170; Drug: placebo; Drug: NNC 90-1170
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified January 2012 - Condition: HIV Related Neurocognitive Impairment
Intervention:
Sponsors: St Stephens Aids Trust; St Stephens Aids Trust
Recruiting - verified January 2012 - Condition: HIV
Interventions: Biological: EN41-FPA2 HIV vaccine; Biological: EN41-FPA2 HIV vaccine; Biological: EN41-FPA2 HIV vaccine; Biological: EN41-FPA2 HIV vaccine; Biological: Na Cl Placebo vaccine
Sponsors: PX'Therapeutics; PX'Therapeutics; European Commission
Recruiting - verified January 2012 - Condition: Endometrial Polyps
Interventions: Device: hysteroscopic morcellator (TruClear); Device: Bipolar Electrical resectoscope (Versapoint)
Sponsors: Birmingham Women's NHS Foundation Trust; Birmingham Women's NHS Foundation Trust; Smith & Nephew, Inc.
Not yet recruiting - verified January 2012 - Conditions: Feeding Patterns; Bone Resorption
Intervention: Other: Overnight fast
Sponsors: QinetiQ Ltd; QinetiQ Ltd; United Kingdom Ministry of Defence
Completed - verified January 2012 - Condition: Fruit and Vegetable Consumption
Interventions: Behavioral: Information-only; Behavioral: Generic appearance intervention; Behavioral: Personalised appearance intervention
Sponsors: Perception Lab; Perception Lab; Unilever R&D
Completed - verified January 2012 - Conditions: Diabetes; Healthy
Interventions: Drug: insulin detemir; Drug: insulin detemir
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011 - Condition: Tuberculosis
Interventions: Biological: Aerosol inhaled MVA85A; Biological: Intradermal MVA85A
Sponsors: University of Oxford; University of Oxford
Recruiting - verified January 2012 - Condition: Obesity
Interventions: Drug: Y242; Drug: 0.9% saline
Sponsors: Imperial College London; Imperial College London; Medical Research Council
Not yet recruiting - verified January 2012 - Conditions: Left Ventricular Function Systolic Dysfunction; Left Ventricular Function Diastolic Dysfunction; Ageing
Intervention: Drug: Ramipril
Sponsors: Newcastle-upon-Tyne Hospitals NHS Trust; Newcastle-upon-Tyne Hospitals NHS Trust
Not yet recruiting - verified January 2012 - Condition: Formulation Finding
Intervention: Drug: RhuDex
Sponsors: MediGene; MediGene
Active, not recruiting - verified May 2012 - Conditions: Overweight; Obesity
Intervention: Behavioral: online lifestyle counseling and a fortified diet beverage
Sponsors: Baylor College of Medicine; Baylor College of Medicine; The Beverage Institute.; Temple University; MRC Human Nutrition Research, Cambridge, UK.; National Development and Research Institutes, Inc.
Completed - verified December 2011 - Condition: Allergy to Mold
Interventions: Other: Air Structuring Protein; Other: Placebo sorbet
Sponsors: Unilever SEAC; Unilever SEAC
Recruiting - verified December 2011 - Condition: Hypercholesterolemia
Intervention: Dietary Supplement: beetroot juice
Sponsors: Queen Mary University of London; Queen Mary University of London; British Heart Foundation
Recruiting - verified December 2011 - Conditions: Diabetes; Healthy
Intervention: Drug: insulin detemir
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011 - Condition: Healthy
Intervention:
Sponsors: University of Oxford; University of Oxford; Okairos
Active, not recruiting - verified May 2012 - Condition: Weight Loss
Intervention: Other: Healthy eating diet (Diet A) or healthy eating diet combined with advice to increase fibre intake (Diet B) to at least 25g/day
Sponsors: University of Leeds; University of Leeds
Active, not recruiting - verified February 2012 - Conditions: Diabetes; Healthy
Intervention: Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified December 2011 - Condition: Huntington Disease
Interventions: Drug: GSK356278; Drug: Rolipram
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified May 2012 - Condition: Congenital Uterine Anomalies
Intervention:
Sponsors: University of Nottingham; University of Nottingham
Not yet recruiting - verified December 2011 - Condition: Preterm Birth
Intervention:
Sponsors: University of Oxford; University of Oxford
Recruiting - verified December 2011 - Condition: Osteoarthritis
Intervention:
Sponsors: University of Nottingham; University of Nottingham
Recruiting - verified April 2012 - Condition: Healthy
Interventions: Drug: MLDL1278A; Drug: MLDL1278A
Sponsors: BioInvent International AB; BioInvent International AB; Genentech
Active, not recruiting - verified March 2012 - Conditions: Cardiovascular; Healthy Subjects; Pharmacokinetics
Interventions: Drug: mirabegron; Drug: tamsulosin
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Completed - verified December 2011 - Conditions: Absorption and Metabolism; Effect on Vascular Function; Effect on Cytokine Concentrations
Intervention: Dietary Supplement: Olive leaf extract capsules
Sponsors: University of Reading; University of Reading; Comvita UK
Completed - verified November 2011 - Condition: Dementia
Interventions: Behavioral: The Talking Sense manual; Behavioral: Treatment as usual - communication information and advice
Sponsors: University of Portsmouth; University of Portsmouth; Solent NHS Primary Care Trust; The Sir Halley Stewart Trust
Recruiting - verified March 2012 - Condition: Cough
Interventions: Drug: GSK2339345 (solution); Drug: GSK2339345 (nebulised); Drug: Placebo (0.9% sodium chloride solution); Drug: Lidocaine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012 - Condition: Healthy Schoolchildren
Intervention: Other: None - observational study
Sponsors: University of Manchester; University of Manchester
Active, not recruiting - verified November 2011 - Condition: Acute Bronchiolitis
Intervention: Device: 3% hypertonic saline
Sponsors: Sheffield Children's NHS Foundation Trust; Sheffield Children's NHS Foundation Trust; University of Sheffield
Recruiting - verified October 2011 - Conditions: Ovarian Cancer; Peritoneal Metastases
Intervention:
Sponsors: Institute of Cancer Research, United Kingdom; Institute of Cancer Research, United Kingdom; Cancer Research UK; Royal Marsden NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Imperial College Healthcare NHS Trust; Northumbria Healthcare NHS Foundation Trust
Not yet recruiting - verified March 2012 - Condition: Overweight
Interventions: Drug: 120 mg orlistat; Drug: 60 mg orlistat; Drug: orlistat experimental dose
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012 - Condition: Chronic Obstructive Pulmonary Disease
Intervention:
Sponsors: Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton & Harefield NHS Foundation Trust
Recruiting - verified December 2011 - Effect of a Unique Web-based Behaviour Change Program on Weight Loss and Cardiovascular Risk FactorsCondition: Obesity
Intervention: Behavioral: Web-based program
Sponsors: Queen's University, Belfast; Queen's University, Belfast; AXA PPP Healthcare
Recruiting - verified November 2011 - Condition: Hepatitis C
Intervention: Drug: Sildenafil and Boceprevir
Sponsors: Imperial College London; Imperial College London
Not yet recruiting - verified December 2011 - Condition: Depression
Interventions: Other: Google Adwords; Other: Local organisation websites
Sponsors: University of Plymouth; University of Plymouth; University of Glasgow
Recruiting - verified November 2011 - Condition: Healthy
Interventions: Drug: MAP0004; Drug: IV DHE (DHE 45) Dihydroergotamine Mesylate; Drug: Ketoconazole
Sponsors: MAP Pharmaceuticals, Inc.; MAP Pharmaceuticals, Inc.
Completed - verified November 2011 - Condition: HIV
Intervention:
Sponsors: St Stephens Aids Trust; St Stephens Aids Trust
Recruiting - verified January 2012 - Conditions: Malaria; Plasmodium Falciparum
Interventions: Biological: Plasmodium falciparum sporozoites; Biological: Plasmodium falciparum sporozoites; Biological: Plasmodium falciparum sporozoites
Sponsors: University of Oxford; University of Oxford; Sanaria Inc (IND Sponsor)
Active, not recruiting - verified December 2011 - Conditions: Pulmonary Arterial Hypertension; Heart Failure
Interventions: Drug: Apelin; Drug: Saline (Placebo); Drug: Saline (Placebo); Drug: Apelin
Sponsors: Golden Jubilee National Hospital; Golden Jubilee National Hospital; NHS Lothian; Imperial College Healthcare NHS Trust
Not yet recruiting - verified October 2011 - Condition: Hirsutism
Interventions: Device: Intense Pulsed Light (IPL); Device: Alexandrite Laser
Sponsors: NHS Greater Glasgow and Clyde; NHS Greater Glasgow and Clyde
Enrolling by invitation - verified May 2012 - Condition: Healthy
Interventions: Dietary Supplement: Glucose; Dietary Supplement: Fructose; Dietary Supplement: Fructan; Dietary Supplement: Fructose and glucose
Sponsors: University of Nottingham; University of Nottingham
Active, not recruiting - verified November 2011 - Conditions: Respiratory Rate; Pulse Oximetry
Interventions: Other: Recording of 12 lead ECG; Other: Recording of lying and standing blood pressure; Other: Recording of chest wall movement; Other: Recording of heart rate variability; Other: Recording of ECG and Pulse oximeter waveform at rest; Other: Recording of ECG and Pulse oximeter waveform during exercise
Sponsors: Guy's and St Thomas' NHS Foundation Trust; Guy's and St Thomas' NHS Foundation Trust; Engineering and physical sciences research council; University of Oxford
Not yet recruiting - verified November 2011 - Condition: No Eye Disease
Intervention:
Sponsors: Optovue; Optovue
Completed - verified May 2012 - Condition: Healthy Volunteers
Interventions: Drug: NI-0501; Drug: Placebo
Sponsors: NovImmune SA; NovImmune SA
Recruiting - verified October 2011 - Condition: Influenza
Interventions: Biological: MVA-NP+M1 and seasonal Influenza vaccine; Biological: Saline placebo and seasonal influenza vaccine
Sponsors: University of Oxford; University of Oxford
Recruiting - verified November 2011 - Condition: Antibody Persistance After Booster Dose of Men C Vaccine
Intervention: Other: Venepuncture and blood sample collection.
Sponsors: University of Oxford; University of Oxford
Not yet recruiting - verified October 2011 - Condition: RSV Infection
Interventions: Drug: MEDI-557; Other: Placebo
Sponsors: MedImmune LLC; MedImmune LLC
Active, not recruiting - verified April 2012 - Conditions: Burns; Smoke Inhalation Injury
Interventions: Behavioral: Injury Prevention Briefing Plus facilitation; Behavioral: Injury Prevention Briefing
Sponsors: University of Nottingham; University of Nottingham
Recruiting - verified October 2011 - Conditions: Smoking; Non-smoking
Intervention: Other: Part A
Sponsors: Philip Morris Products S.A.; Philip Morris Products S.A.
Completed - verified December 2011 - Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Drug: GSK1325756
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012 - Conditions: Alzheimer's Disease; Schizophrenia
Interventions: Drug: amisulpride; Drug: amisulpride; Drug: amisulpride
Sponsors: Institute of Psychiatry, London; Institute of Psychiatry, London
Not yet recruiting - verified October 2011 - Condition: Chronic Pancreatitis
Intervention: Drug: Secretin
Sponsors: University of Nottingham; University of Nottingham
Completed - verified October 2011 - Condition: Parkinson's Disease
Interventions: Drug: AZD3241 ER formulation 1; Drug: Placebo; Drug: AZD3241 Alternative titration scheme with formulation 1 or 2
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified November 2011 - Condition: Chronic Cough
Interventions: Drug: Placebo; Drug: SB-705498
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012 - Condition: Mosquito Bite
Interventions: Drug: NSAI treatment; Drug: Steroid treatment
Sponsors: London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine
Not yet recruiting - verified October 2011 - Conditions: Mental and Behavioral Disorders; Withdrawal State
Intervention: Drug: Nicotine
Sponsors: Queen Mary University of London; Queen Mary University of London
Not yet recruiting - verified May 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: GSK961081 800 microgramme dose; Drug: Fluticasone Propionate 500 microgramme dose; Drug: GSK961081 800 microgramme and Fluticasone Propionate 500 microgramme separately; Drug: GSK961081 800 microgramme Fluticasone Propionate 500 microgrammes in a blend
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified May 2012 - Condition: Asthma
Interventions: Drug: GSK2269557; Drug: GSK2269557 matching placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified February 2012 - Conditions: Diabetes; Healthy
Intervention: Drug: human insulin
Sponsors: Novo Nordisk; Novo Nordisk
Completed - verified October 2011 - Condition: Healthy
Intervention: Drug: [14C]NXL104
Sponsors: AstraZeneca; AstraZeneca
Completed - verified December 2011 - Condition: Healthy Volunteers - Influenza A and/or B (GSK Biologicals' Influenza Candidate Vaccine GSK2321138A)
Interventions: Biological: Influenza vaccine GSK2321138A; Biological: Havrix Junior; Biological: Wyeth Prevenar; Biological: Sanofi Pasteur Varivax/ProVarivax; Biological: Varilrix
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Condition: Obesity
Interventions: Drug: AZD2820; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Pain, Neuropathic
Interventions: Drug: Gabapentin lower dose; Drug: Donepezil; Other: Placebo (Dop); Other: Placebo (Gaba); Drug: Gabapentin higher dose
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Esophageal Motility Disorders
Interventions: Drug: Azithromycin; Drug: Placebo
Sponsors: Queen Mary University of London; JAFAR JAFARI
Not yet recruiting - verified October 2011 - Condition: Healthy
Interventions: Drug: AZD2115; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified April 2012 - Condition: Invasive Pneumococcal Disease
Interventions: Biological: 13-valent pneumococcal conjugate vaccine; Biological: 10-valent pneumococcal conjugate vaccine
Sponsors: University of Oxford; University of Oxford
Not yet recruiting - verified September 2011 - Condition: Atrophy, Muscular
Intervention: Other: MRI scan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011 - Condition: Healthy
Interventions: Drug: Capsule ASA 81mg/esomeprazole 20mg; Drug: Acetylsalicylzuur Apotex Cardio
Sponsors: AstraZeneca; AstraZeneca
Completed - verified May 2012 - Condition: Cholestasis of Pregnancy
Intervention:
Sponsors: Imperial College London; Imperial College London
Recruiting - verified December 2011 - Condition: Elevated LDL-Cholesterol (LDL-C)
Interventions: Drug: ALN-PCS02; Drug: Sterile Normal Saline (0.9% NaCl)
Sponsors: Alnylam Pharmaceuticals; Alnylam Pharmaceuticals
Active, not recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Insulin glargine; Drug: Insulin detemir
Sponsors: Buckinghamshire Healthcare NHS Trust; Buckinghamshire Healthcare NHS Trust; Novo Nordisk
Recruiting - verified November 2011 - Condition: Pneumococcal Disease
Interventions: Biological: Prevenar 13; Biological: Pneumovax II
Sponsors: University of Oxford; University of Oxford; Mason Medical Research Foundation
Not yet recruiting - verified August 2011 - Condition: Healthy
Interventions: Drug: CAZ104; Drug: Avibactam; Drug: Ceftazidime
Sponsors: AstraZeneca; AstraZeneca
Suspended - verified December 2011 - Condition: Osteoporosis
Interventions: Device: Strain Gauge; Other: Vibration therapy
Sponsors: Sheffield Teaching Hospitals NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation Trust; NIHR Biomedical Research Unit funding
Recruiting - verified September 2011 - Condition: Healthy Subjects
Interventions: Drug: LY2140023; Drug: Ammonium chloride; Drug: Sodium bicarbonate
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified October 2011 - Condition: Multiple Sclerosis
Intervention: Radiation: [18F]PBR111
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012 - Condition: Drug Safety
Intervention: Behavioral: DQIP Intervention
Sponsors: University of Dundee; University of Dundee; NHS Tayside; NHS Fife
Recruiting - verified August 2011 - Condition: Healthy Volunteer Study
Interventions: Drug: HF1020; Drug: HF1020 placebo
Sponsors: Trident Pharmaceuticals Inc; Trident Pharmaceuticals Inc
Completed - verified October 2011 - Condition: Streptococcus Pneumoniae
Intervention:
Sponsors: Health Protection Agency, United Kingdom; Dr. Elizabeth Miller
Recruiting - verified March 2012 - Condition: Carcinoid Syndrome
Intervention:
Sponsors: Sheffield Teaching Hospitals NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation Trust; NIHR Biomedical Research Unit for Musculoskeletal Disease
Recruiting - verified September 2011 - Condition: Endometriosis
Interventions: Procedure: Surgery for ovarian endometrioma; Procedure: Surgery for ovarian endometrioma
Sponsors: Derby Hospitals NHS Foundation Trust; Saad Amer; Derby Hospitals NHS Foundation Trust
Recruiting - verified August 2011 - Condition: Depressive Disorder
Interventions: Radiation: [11C]PHNO; Drug: Aripiprazole
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified September 2011 - Conditions: Healthy Volunteers; Chuvash Polycythaemia
Intervention: Other: Commercial airline flight
Sponsors: University of Oxford; University of Oxford
Completed - verified August 2011 - Condition: Glycemic Index of a Meal
Interventions: Other: Palaeolithic meal 1; Other: Palaeolithic meal 2; Other: Reference meal
Sponsors: Unilever R&D; Unilever R&D; Leatherhead Food Research
Completed - verified February 2012 - Condition: Sepsis
Intervention: Biological: Lipopolysaccharide infusion
Sponsors: University of Nottingham; University of Nottingham
Recruiting - verified October 2011 - Condition: Clinical Skills Training
Interventions: Other: Emergency Psychiatry Immersion Course; Other: Observed SKills in the Emergency Room
Sponsors: King's College London; King's College London; Guy's and St Thomas' NHS Foundation Trust; South London and Maudsley Charitable Funds; South London and Maudsley NHS Foundation Trust
Active, not recruiting - verified August 2011 - Condition: Nicotine Withdrawal
Interventions: Behavioral: Stress Ball vs Nicotine-free E-Cigarette; Behavioral: Nicotine-free E-Cigarette vs De-nicotinised Cigarette
Sponsors: Queen Mary University of London; Queen Mary University of London
Not yet recruiting - verified August 2011 - Condition: Life Experiences
Interventions: Other: Information Sheet; Other: Consent; Other: interview; Other: Debrief
Sponsors: University of East London; University of East London
Recruiting - verified August 2009 - Condition: Healthy
Interventions: Drug: AZD8683; Drug: Placebo to match
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Single dose reduced; Drug: Single dose standard; Drug: Multiple Dose; Drug: Multiple Dose
Sponsors: Biogen Idec; Biogen Idec
Completed - verified March 2012 - Conditions: Typhoid Fever; Enteric Fever; Typhoid
Interventions: Biological: Vaccine placebo (excipients only); Biological: Ty21a; Biological: M10ZH09 vaccine
Sponsors: University of Oxford; University of Oxford; Wellcome Trust; Imperial College London; University of Maryland
Recruiting - verified December 2011 - Conditions: Healthy; Diabetes Mellitus, Type 2
Interventions: Drug: oral NNC 0113-0987; Drug: oral NNC 0113-0987; Drug: I.v. NNC 0113-0987; Drug: oral placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012 - Condition: Human Immunodeficiency Virus
Intervention: Drug: P2G12
Sponsors: University of Surrey; University of Surrey; European Commission
Completed - verified December 2011 - Condition: Postmenopausal Osteoporosis
Intervention: Other: Observation
Sponsors: Sheffield Teaching Hospitals NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation Trust; NIHR Biomedical Research Unit for Musculoskeletal Disease
Recruiting - verified August 2011 - Condition: Mild Stress/Anxiety
Intervention: Drug: Vitano
Sponsors: University of Surrey; University of Surrey; Dr. Willmar Schwabe GmbH & Co. KG
Completed - verified August 2010 - Study to Examine the Effect of Ulimorelin on the Pharmacokinetics of Midazolam in Healthy VolunteersCondition: Digestive System Disorders
Interventions: Drug: Midazolam; Drug: Ulimorelin
Sponsors: Norgine; Norgine
Recruiting - verified July 2011 - Condition: Children
Intervention:
Sponsors: University of Bristol; University of Bristol
Completed - verified July 2011 - Condition: Keratoconus
Interventions: Procedure: Artemis Ultrasound Exam; Procedure: ARFI Ultrasound exam
Sponsors: Columbia University; Columbia University; National Eye Institute (NEI)
Recruiting - verified February 2012 - Condition: Hypertension
Intervention: Dietary Supplement: beetroot juice
Sponsors: Queen Mary University of London; Queen Mary University of London
Recruiting - verified May 2012 - Condition: Type 1 Diabetes Mellitus
Intervention:
Sponsors: Buckinghamshire Healthcare NHS Trust; Buckinghamshire Healthcare NHS Trust; Animas Corporation
Completed - verified November 2011 - Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and PlasmaCondition: Healthy
Interventions: Drug: CAZ104; Drug: CAZ104
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Atopic Dermatitis
Interventions: Drug: LEO 29102; Drug: Placebo
Sponsors: LEO Pharma; LEO Pharma
Recruiting - verified April 2012 - Condition: Healthy Volunteers
Interventions: Drug: Levetiracetam; Drug: Levetiracetam
Sponsors: UCB, Inc.; UCB, Inc.
Completed - verified October 2011 - Condition: Type 1 Diabetes
Intervention: Other: Reduction of basal insulin infusion to 50% of normal
Sponsors: Buckinghamshire Healthcare NHS Trust; Buckinghamshire Healthcare NHS Trust; Animas Corporation
Terminated - verified July 2011 - Conditions: Migraine; Cluster Headache; Control; Menstrual Migraine
Intervention:
Sponsors: University College London Hospitals; University College London Hospitals
Not yet recruiting - verified May 2011 - Condition: Lung Cancer
Interventions: Drug: nelfinavir; Radiation: Radical Radiotherapy
Sponsors: Oxford University Hospitals NHS Trust; Oxford University Hospitals NHS Trust
Not yet recruiting - verified December 2011 - Condition: Healthy
Interventions: Device: All-in-One Light multipurpose; Device: Aquify care
Sponsors: Sauflon Pharmaceuticals Ltd; Sauflon Pharmaceuticals Ltd
Completed - verified July 2011 - Condition: Healthy Post Menopausal Women
Interventions: Drug: ONO-5334; Drug: ONO-5334
Sponsors: Ono Pharma; Ono Pharma
Active, not recruiting - verified December 2011 - Conditions: Hyperopia; Myopia
Interventions: Device: Air Optix Aqua; Device: Clariti
Sponsors: Sauflon Pharmaceuticals Ltd; Sauflon Pharmaceuticals Ltd
Completed - verified July 2011 - Condition: Healthy Volunteers
Interventions: Drug: PF-06273588; Drug: PF-06273588
Sponsors: Pfizer; Pfizer
Completed - verified September 2011 - Condition: Healthy Volunteer
Interventions: Drug: Marketed paracetamol; Drug: Experimental paracetamol formulation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Withdrawn - verified March 2012 - Condition: Impact of Food Composition on Gastric Emptying
Intervention: Other: Food type
Sponsors: Institute of Food Research; Institute of Food Research; Norfolk and Norwich University Hospitals NHS Foundation Trust
Completed - verified June 2011 - Condition: Heart Failure
Interventions: Drug: placebo; Drug: omecamtiv mecarbil; Drug: omecamtiv mecarbil; Drug: omecamtiv mecarbil; Drug: omecamtiv mecarbil; Drug: omecamtiv mecarbil; Drug: omecamtiv mecarbil; Drug: omecamtiv mecarbil; Drug: omecamtiv mecarbil; Drug: omecamtiv mecarbil; Drug: omecamtiv mecarbil
Sponsors: Cytokinetics; Cytokinetics
Completed - verified June 2011 - Condition: Persistent Atrial Fibrillation
Interventions: Procedure: Thoracoscopically Assisted Surgical Ablation; Procedure: Catheter Ablation
Sponsors: Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton & Harefield NHS Foundation Trust
Enrolling by invitation - verified June 2011 - Condition: Autoimmune Diseases
Interventions: Drug: Azithromycin - 250 mg; Drug: Azithromycin - 1000 mg; Drug: Azithromycin - 250 mg every other day for 3 weeks
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012 - Condition: Parkinson Disease
Interventions: Genetic: Healthy; Genetic: PKD Patients
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified February 2012 - Condition: Depression
Interventions: Drug: Metyrapone; Drug: placebo
Sponsors: Northumberland, Tyne and Wear NHS Foundation Trust; Northumberland, Tyne and Wear NHS Foundation Trust; National Institute for Health Research, Efficacy and Mechanism Evaluation Programme
Recruiting - verified April 2011 - Condition: Healthy Volunteer
Interventions: Drug: Paracetamol formulation 1; Drug: Paracetamol formulation 2
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012 - Condition: Healthy Adult Subjects
Interventions: Drug: ONO-4053; Drug: Placebo
Sponsors: Ono Pharma; Ono Pharma
Terminated - verified January 2012 - Condition: Dry Eye
Interventions: Drug: Next Generation Emulsion; Drug: Refresh Dry Eye Therapy; Drug: Refresh Contacts
Sponsors: Glasgow Caledonian University; Glasgow Caledonian University; Allergan
Not yet recruiting - verified February 2011 - Conditions: Mood Modulation; Modulation of Cognition
Interventions: Dietary Supplement: Hops Extract; Other: Placebo (silica)
Sponsors: Northumbria University; Northumbria University; The New Zealand Institute for Plant and Food Research
Recruiting - verified August 2011 - Condition: Cardiovascular Diseases
Interventions: Dietary Supplement: Low fat diet; Dietary Supplement: Hgih saturated fat diet; Dietary Supplement: High saturated fat diet
Sponsors: University of Reading; University of Reading; Wellcome Trust
Completed - verified June 2011 - Conditions: Colon Cancer; Breast Cancer; Trauma; Inflammatory Bowel Disease; Hernia
Intervention:
Sponsors: Imperial College London; Imperial College London
Not yet recruiting - verified July 2011 - Conditions: Cognitive Function; Mood; Cerebral Haemodynamics; Caffeine Withdrawal
Interventions: Dietary Supplement: Placebo; Dietary Supplement: Caffeine and Placebo; Dietary Supplement: Placebo and Caffeine; Dietary Supplement: Caffeine
Sponsors: Northumbria University; Northumbria University
Recruiting - verified June 2011 - Conditions: Schizophrenia; Healthy Volunteer
Interventions: Drug: GSK1144814; Drug: GSK1144814; Drug: GSK1144814
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011 - Condition: Healthy
Interventions: Drug: ASP015K; Drug: ASP015K
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Completed - verified September 2011 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Propionate; Drug: Placebo for Fluticasone Propionate
Sponsors: Pfizer; Pfizer
Completed - verified February 2012 - Conditions: Anemia; Chronic Diseases; Inflammation
Interventions: Drug: NOX-H94; Other: Glucose 5%
Sponsors: Noxxon Pharma AG; Noxxon Pharma AG
Completed - verified March 2012 - Condition: Cognition
Intervention: Dietary Supplement: Grape juice polyphenols
Sponsors: University of Leeds; University of Leeds; Welch's, Inc.
Active, not recruiting - verified August 2011 - Condition: Healthy Subjects
Intervention: Drug: Ketorolac tromethamine
Sponsors: Luitpold Pharmaceuticals; Luitpold Pharmaceuticals
Completed - verified June 2011 - Conditions: Obstructive Jaundice; Disease as Reason for ERCP; Immune Dysfunction; Immune Tolerance
Intervention:
Sponsors: University of Nottingham; University of Nottingham
Recruiting - verified August 2011 - Condition: HIV Infections
Interventions: Biological: DNA.HIVA; Biological: MVA.HIVA; Biological: MVA.HIVA; Biological: MVA.HIVA
Sponsors: International AIDS Vaccine Initiative; International AIDS Vaccine Initiative; Medical Research Council-Oxford; University of Nairobi
Completed - verified June 2011 - Condition: Malaria
Interventions: Biological: Vaccination Schedule One; Biological: Vaccination Schedule Two; Biological: Vaccination Schedule Three; Biological: Vaccination Schedule Four; Biological: Vaccination Schedule Five; Biological: Vaccination Schedule Six; Biological: Vaccination Schedule Seven
Sponsors: University of Oxford; University of Oxford
Recruiting - verified July 2011 - Condition: Infertility
Intervention:
Sponsors: Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge Temperature Concepts
Active, not recruiting - verified January 2011 - Conditions: Attention Deficit Hyperactivity Disorder; ADHD; Bipolar Disorder
Intervention:
Sponsors: King's College London; King's College London; South London and Maudsley NHS Trust (SLAM)
Recruiting - verified April 2012 - Condition: Myopia
Interventions: Device: senfilcon A contact lens; Device: investigational enfilcon A
Sponsors: Coopervision, Inc.; Coopervision, Inc.
Completed - verified April 2012 - Conditions: Healthy Volunteers; Rheumatoid Arthritis
Interventions: Drug: Digoxin; Drug: Fostamatinib
Sponsors: AstraZeneca; AstraZeneca
Completed - verified October 2011 - Condition: Exercise Fat Oxidation
Interventions: Dietary Supplement: High calcium milk; Dietary Supplement: Control
Sponsors: Northumbria University; Northumbria University
Completed - verified May 2012 - Conditions: Anemia, Sickle Cell; Sickle Cell Anemia; Sickle Cell Disease; Sickle Cell Disorders; Hemoglobin SC Disease; Sickle Cell Hemoglobin C Disease
Interventions: Drug: MP4CO; Drug: Sodium chloride solution
Sponsors: Sangart; Sangart
Recruiting - verified May 2012 - Condition: Motor Activity
Interventions: Other: cocoa-based food; Other: cocoa-based food
Sponsors: Nestle Research Center; Nestle Research Center
Completed - verified January 2012 - Conditions: Insulin Resistance; Obesity; Dyslipidemia
Intervention: Dietary Supplement: Citrus Flavonoids
Sponsors: University of Nottingham; University of Nottingham; Florida Department of Citrus
Recruiting - verified January 2012 - Condition: Malaria
Interventions: Biological: AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909; Biological: AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909; Biological: AdCh63 AMA1 + AMA1-C1/Alhydrogel®; Biological: AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909; Biological: AdCh63 AMA1 + MVA AMA1
Sponsors: University of Oxford; University of Oxford; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2011 - Conditions: Alzheimer's Disease; Safety; Tolerability; Blood Concentration; Healthy Volunteers
Interventions: Drug: AZD3839; Drug: AZD3839 Placebo
Sponsors: AstraZeneca; AstraZeneca
Completed - verified April 2012 - Condition: Dry Eye
Interventions: Other: Systane Balance Lubricating Eye Drops; Other: OPTIVE™
Sponsors: Alcon Research; Alcon Research; Optometric Technology Group Ltd
Completed - verified January 2012 - Condition: Healthy Male
Interventions: Drug: TC-5214; Other: Placebo comparator; Drug: Moxifloxacin; Other: Moxifloxacin placebo comparator
Sponsors: AstraZeneca; AstraZeneca
Terminated - verified April 2012 - Condition: Missing Teeth
Interventions: Procedure: Zirconia-based adhesive bridge; Procedure: Metal-based adhesive bridge
Sponsors: Queen Mary University of London; Queen Mary University of London
Not yet recruiting - verified January 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: SRT3025; Drug: Placebo
Sponsors: GlaxoSmithKline; Sirtris, a GSK Company; GlaxoSmithKline
Completed - verified February 2012 - Condition: Healthy Volunteers
Intervention: Drug: [14C] NKTR-118
Sponsors: AstraZeneca; AstraZeneca
Completed - verified September 2011 - Conditions: Study Focus 1:Glycaemic Index; Study Focus 2:Glycaemic Response; Study Focus 3:Insulinemic Response
Interventions: Other: Dietary Intervention; Other: Dietary Intervention; Other: Dietary Intervention; Other: Dietary Intervention
Sponsors: Kraft Foods; Kraft Foods; Reading Scientific Services Limited (RSSL)
Withdrawn - verified June 2011 - Conditions: Schizophrenia; Mental Disorders
Interventions: Drug: Drug; Drug: Drug
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011 - Condition: Asthma
Interventions: Drug: Rosuvastatin 10 mg; Drug: GSK2190915 30mg; Drug: GSK2190915 100mg
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified August 2011 - Condition: Obesity
Intervention:
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Terminated - verified May 2011 - Condition: Healthy Volunteers
Intervention: Other: cross-linking of an emulsion drink
Sponsors: Institute of Food Research; Institute of Food Research; Norfolk and Norwich University Hospitals NHS Foundation Trust
Recruiting - verified March 2012 - Condition: Chronic Obstructive Pulmonary Disease
Intervention: Drug: PUR118
Sponsors: Pulmatrix Inc.; Pulmatrix Inc.; Quotient Bioresearch
Recruiting - verified November 2011 - Condition: Healthy
Interventions: Drug: AZD2820; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Completed - verified November 2011 - Conditions: Influenza; Common Cold
Interventions: Drug: Hot drink remedy; Drug: Paraetamol tablet
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011 - Condition: Amyloidosis
Interventions: Drug: GSK2315698; Drug: GSK2315698
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified July 2011 - Condition: Healthy
Interventions: Drug: AZD8931; Drug: AZD8931
Sponsors: AstraZeneca; AstraZeneca
Completed - verified July 2011 - Condition: Orthodontic Treatment
Intervention: Device: Conventional orthodontic bracket, passive self-ligating brackets and active self-ligating bracket
Sponsors: Barts & The London NHS Trust; Barts & The London NHS Trust; East Kent Hospitals University NHS Foundation Trust; Southend NHS Foundation Trust
Active, not recruiting - verified April 2012 - Conditions: Haematological Malignancies; Allogeneic Stem Cell Transplant; CD56+CD3- NK Cells
Interventions: Procedure: Infusion of donor derived ex-vivo selected NK cells to patients after transplant; Procedure: Haematology / Blood chemistry sampling
Sponsors: Imperial College London; Imperial College London
Withdrawn - verified March 2012 - Conditions: Acute Respiratory Distress Syndrome (ARDS); Acute Lung Injury (ALI)
Interventions: Drug: GSK1995057 single dose; Drug: GSK1995057 repeat dose
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified November 2011 - Conditions: Healthy Volunteers; Bioequivalence
Interventions: Drug: VIMOVO (AstraZeneca); Drug: VIMOVO (Patheon); Drug: Marketed enteric-coated naproxen formulation
Sponsors: AstraZeneca; AstraZeneca
Completed - verified October 2011 - Condition: Depression
Intervention: Behavioral: Intervention: Exercise and motivational interviewing
Sponsors: University of Nottingham; University of Nottingham; National Institute for Health Research, United Kingdom
Recruiting - verified November 2011 - Condition: Neurodegeneration
Intervention: Other: Fruit juice beverage
Sponsors: University of Reading; University of Reading
Completed - verified November 2011 - Condition: Nerve Degeneration
Interventions: Dietary Supplement: High flavanone orange juice; Dietary Supplement: Control orange juice
Sponsors: University of Reading; University of Reading
Completed - verified November 2011 - Condition: Healthy
Intervention: Drug: [14C] AZD5069
Sponsors: AstraZeneca; AstraZeneca
Completed - verified July 2011 - Condition: Childbirth Related Levator Injuries
Intervention:
Sponsors: Croydon University Hospital; Croydon University Hospital
Recruiting - verified April 2012 - Condition: Healthy Subjects
Intervention: Drug: LEO 32731
Sponsors: LEO Pharma; LEO Pharma
Recruiting - verified March 2011 - Conditions: Rheumatoid Arthritis; Healthy Subjects
Interventions: Drug: warfarin; Drug: fostamatinib
Sponsors: AstraZeneca; AstraZeneca
Completed - verified June 2011 - Condition: Healthy
Interventions: Drug: ATX-101; Drug: ATX-101; Drug: Placebo
Sponsors: Kythera Biopharmaceuticals; Kythera Biopharmaceuticals; Intendis GmbH
Active, not recruiting - verified February 2012 - Condition: Healthy
Interventions: Drug: ATX-101; Drug: ATX-101; Drug: Placebo
Sponsors: Kythera Biopharmaceuticals; Kythera Biopharmaceuticals; Intendis GmbH
Active, not recruiting - verified February 2012 - Conditions: Healthy; Asthma
Interventions: Drug: AZD5423; Drug: AZD5423; Drug: AZD5423; Drug: AZD5423
Sponsors: AstraZeneca; AstraZeneca
Completed - verified October 2011 - Condition: Hepatitis C Infection
Interventions: Biological: MVA-NSmut; Biological: AdCh3NSmut; MVA-NSmut; Biological: AdCh3NSmut; MVA-NSmut; Biological: AdCh3NSmut ; MVA-NSmut; Biological: AdCh3NSmut; MVA-NSmut
Sponsors: Okairos; Okairos; University of Oxford; Oxford University Hospitals NHS Trust; University Hospital Birmingham
Recruiting - verified October 2011 - Conditions: Chronic Obstructive Airway Disease; Asthma; Chronic Cough
Interventions: Other: Cough Challenge Tests; Other: ambulatory cough recording; Other: Cough questionnaires
Sponsors: University Hospital of South Manchester NHS Foundation Trust; University Hospital of South Manchester NHS Foundation Trust
Completed - verified September 2011 - Conditions: Cardiovascular Disease; Heart Failure
Interventions: Drug: Urocortin 2; Drug: Urocortin 3
Sponsors: University of Edinburgh; University of Edinburgh; NHS Lothian
Completed - verified August 2011 - Condition: Infant Newborn
Interventions: Other: Human Milk; Other: Investigational infant formula; Other: Milk based standard infant formula
Sponsors: Abbott Nutrition; Abbott Nutrition; Institute of Child Health
Recruiting - verified November 2011 - Condition: Huntington's Disease
Intervention:
Sponsors: CHDI Foundation, Inc.; CHDI Foundation, Inc.; Monash University
Recruiting - verified February 2012 - Condition: Gastrointestinal Motility
Interventions: Drug: Active; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011 - A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United KingdomCondition: Chronic Cough
Interventions: Procedure: Cough swab; Procedure: Oropharyngeal swab; Procedure: Nasopharyngeal swabs; Procedure: Blood sample; Procedure: Bronchoscopy/ bronchoalveolar lavage samples; Other: Data collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012 - Condition: Healthy
Intervention: Drug: [14C] AZD8931
Sponsors: AstraZeneca; AstraZeneca
Completed - verified June 2011 - Condition: HIV Infections
Intervention: Biological: CN54gp140 glycoprotein-hsp70 conjugate vaccine
Sponsors: St George's, University of London; St George's, University of London; European Union
Active, not recruiting - verified October 2011 - Condition: High Altitude Headache
Interventions: Drug: Acetazolamide; Drug: Lactose monohydrate
Sponsors: Bangor University; Bangor University; Research Center for Sport, Mountain and Health of Rovereto, University of Verona, Italy; North Wales Research Committee, UK
Completed - verified December 2011 - Condition: Suspected Arterial Hypertension
Intervention: Other: no intervention performed
Sponsors: Klinikum Wels-Grieskirchen; Klinikum Wels-Grieskirchen; Austrian Society of Hypertension (Werner Klein Stipendium); Government of lower Austria and European Funds for Regional Development (WST3-T-81/015-2008); I.E.M. (Stolberg, Germany) - unrestricted grant
Recruiting - verified October 2011 - Conditions: Scientific Terminology Rheumatoid Arthritis, Healthy Female Volunteers, Pharmacokinetics, Oral Contraceptive, Drug-drug Interaction; Laymen Terminology Level of Oral Contraceptive in Blood, Oral Contraceptive, Rheumatoid Arthritis, Drug -Drug Interaction
Interventions: Drug: fostamatinib; Drug: Microgynon® 30 (Oral contraceptive); Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Completed - verified February 2012 - Condition: HIV Infection
Interventions: Drug: TMC278LA; Drug: TMC278LA; Drug: TMC278LA; Drug: TMC278LA
Sponsors: St Stephens Aids Trust; St Stephens Aids Trust
Active, not recruiting - verified February 2012 - Conditions: Chronic Obstructive Pulmonary Disease; Lung Disease Causing Persistent Narrowing of the Airways
Interventions: Drug: AZD2115; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Completed - verified August 2011 - Conditions: Pregnancy Complications; Obesity
Interventions: Drug: Metformin; Drug: Placebo
Sponsors: Epsom and St Helier University Hospitals NHS Trust; Epsom and St Helier University Hospitals NHS Trust; Fetal Medicine Foundation; King's College Hospital NHS Trust
Recruiting - verified January 2012 - Condition: Pregnancy
Intervention:
Sponsors: SPD Development Company Limited; SPD Development Company Limited
Completed - verified September 2011 - Conditions: Pulmonary Disease, Chronic Obstructive; Healthy Volunteers
Interventions: Drug: GSK1325756; Drug: Sugar Pill
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified August 2011 - Condition: Influenza
Interventions: Biological: FP-01.1; Biological: placebo
Sponsors: Immune Targeting Systems Ltd; Immune Targeting Systems Ltd; Hammersmith Medicines Research
Completed - verified March 2012 - Condition: Contraception
Interventions: Drug: BAY86-5300; Drug: BAY86-5300
Sponsors: Bayer; Bayer
Active, not recruiting - verified February 2012 - Condition: Healthy Volunteers
Interventions: Biological: CDP6038; Biological: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Completed - verified September 2011 - Condition: Asthma
Interventions: Drug: AZD1981, 2000mg; Drug: AZD1981, 200mg; Drug: Moxifloxacin, 400mg; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Completed - verified June 2011 - Condition: Gastroparesis
Interventions: Drug: GSK962040 (5 mg tablet); Drug: GSK962040 (25 mg tablet); Drug: GSK962040 (125 mg tablet); Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Healthy Volunteers
Interventions: Drug: Atorvastatin; Biological: LY2189265
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified October 2011 - Condition: Hepatitis B
Intervention: Biological: 1 dose at Day 1
Sponsors: Sanofi Pasteur MSD; Sanofi Pasteur MSD
Completed - verified October 2011 - Conditions: Poliomyelitis; Rubella; Diphtheria; Pertussis; Mumps; Measles; Tetanus
Interventions: Biological: Boostrix PolioTM; Biological: RepevaxTM; Biological: PriorixTM
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified May 2012 - Conditions: Smoking Cessation; Tobacco Dependence
Interventions: Other: De-nicotinised cigarettes + standard treatment; Other: Standard Treatment
Sponsors: Queen Mary University of London; Queen Mary University of London; Pfizer
Active, not recruiting - verified March 2012 - Condition: Heart Failure, Congestive
Intervention: Procedure: MRI
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011 - Condition: Gastroparesis
Interventions: Drug: A; Drug: B
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified July 2011 - Conditions: Taste Receptors; Nutrient Sensing; Intestinal Absorption; Blood Glucose; Appetite
Intervention: Dietary Supplement: Artificial Sweeteners
Sponsors: Northumbria University; Northumbria University
Withdrawn - verified May 2012 - Condition: Tuberculosis
Interventions: Biological: C-Tb; Biological: 2 TU Tuberculin PPD RT 23 SSI
Sponsors: Statens Serum Institut; Statens Serum Institut
Completed - verified February 2012 - Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: PF-03715455; Drug: PH-797804; Drug: Placebo for PF-03715455; Drug: Placebo for PH-797804
Sponsors: Pfizer; Pfizer
Completed - verified February 2012 - Condition: Insomnia
Interventions: Drug: LY2624803; Other: Activated Charcoal
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified November 2011 - Condition: Chronic Periodontitis
Intervention:
Sponsors: NHS South Birmingham; NHS South Birmingham; University of Birmingham
Not yet recruiting - verified July 2010 - Conditions: Asthma; Health
Intervention: Other: All patients
Sponsors: Centocor, Inc.; Centocor, Inc.
Recruiting - verified May 2012 - Conditions: Haemophilia A; Haemophilia B; Healthy
Interventions: Drug: NNC 0172-0000-2021; Drug: NNC 0172-0000-2021; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 1
Intervention: Procedure: two step hyperinsulinaemic glucose clamp study.
Sponsors: The Royal Bournemouth Hospital; The Royal Bournemouth Hospital
Suspended - verified July 2011 - Conditions: Energy Balance,; Appetite,; Cognitive Function.
Intervention: Drug: Breakfast & exercise
Sponsors: Northumbria University; Northumbria University
Completed - verified May 2012 - Conditions: Postprandial Glycaemia,; Postprandial Insulinaemia; Appetite
Intervention: Drug: Test meal
Sponsors: Northumbria University; Northumbria University
Completed - verified May 2012 - Conditions: Type 2 Diabetes; Obesity
Intervention: Drug: AZD7687
Sponsors: AstraZeneca; AstraZeneca
Completed - verified February 2012 - Condition: N. Meningitidis Carriage
Interventions: Biological: Meningococcal vaccines; Biological: Meningococcal vaccines; Biological: Meningococcal vaccines
Sponsors: Novartis; Novartis Vaccines
Active, not recruiting - verified January 2012 - Condition: Colorectal Cancer
Interventions: Dietary Supplement: Maltodextrin and Amioca starch; Dietary Supplement: Hi-maize 260; Dietary Supplement: Polydextrose; Dietary Supplement: Hi-maize 260 and polydextrose
Sponsors: Newcastle University; Newcastle University; Northumbria Healthcare NHS Foundation Trust
Active, not recruiting - verified October 2011 - Condition: Partial Onset Epilepsy
Interventions: Drug: Perampanel and Microgynon-30; Drug: Perampanel and Microgynon-30
Sponsors: Eisai Inc.; Eisai Inc.
Completed - verified January 2011 - Condition: Poisoning
Interventions: Drug: Chlorphenamine and Ranitidine; Drug: Paracetamol; Drug: Paracetamol
Sponsors: University of Edinburgh; University of Edinburgh; NHS Lothian
Recruiting - verified September 2010 - Condition: Prematurity
Interventions: Other: preterm infant formula with high protein levels; Other: preterm standard infant formula
Sponsors: Nestlé Nutrition Corporate; Nestlé Nutrition Corporate
Terminated - verified December 2011 - Conditions: Quorum Sensing; Prebiotics; Probiotics; Sepsis
Interventions: Dietary Supplement: Bifidobacterium longum BB536; Dietary Supplement: Active hexose correlated compound (AHCC); Dietary Supplement: Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC); Dietary Supplement: Corn starch placebo capsule; Drug: Azithromycin
Sponsors: University of Nottingham; University of Nottingham
Completed - verified May 2011 - Condition: Irritable Bowel Syndrome With Diarrhoea
Interventions: Drug: Mesalazine; Drug: Placebo
Sponsors: University of Nottingham; University of Nottingham; National Institute for Health Research, United Kingdom
Recruiting - verified January 2012 - Conditions: Insulin Resistance; Obesity
Intervention: Dietary Supplement: orange juice
Sponsors: University of Nottingham; University of Nottingham; Florida Department of Citrus
Active, not recruiting - verified January 2012 - Conditions: Tobacco Dependence; Smoking Cessation
Interventions: Drug: Varenicline; Drug: Placebo; Drug: Varenicline
Sponsors: Queen Mary University of London; Queen Mary University of London
Recruiting - verified July 2011 - Condition: Haploidentical Stem Cell Transplantation
Intervention: Biological: HSVTK retrovirally-transduced donor T lymphocytes
Sponsors: Great Ormond Street Hospital for Children NHS Trust; Great Ormond Street Hospital for Children NHS Trust
Recruiting - verified March 2012 - Condition: Obesity
Interventions: Drug: GSK1521498; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012 - Condition: Asthma
Interventions: Biological: CNTO 3157 or placebo; Biological: CNTO 3157 or placebo; Biological: CNTO 3157 or placebo; Biological: CNTO 3157 or placebo; Biological: CNTO 3157 or placebo; Biological: CNTO 3157 or placebo; Biological: CNTO 3157 or placebo; Biological: CNTO 3157 or placebo
Sponsors: Centocor, Inc.; Centocor, Inc.
Completed - verified February 2012 - Condition: Tuberculosis
Interventions: Biological: BCG: 100 microlitres ~ 2-8 x 105 pfu; Biological: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu
Sponsors: University of Oxford; University of Oxford
Recruiting - verified October 2011 - Conditions: Tobacco Dependence; Smoking Cessation
Interventions: Drug: Nicotine Patch; Drug: Placebo; Drug: Varenicline
Sponsors: Queen Mary University of London; Queen Mary University of London
Completed - verified October 2011 - Condition: Astigmatism
Interventions: Device: Senofilcon A Toric; Device: Etafilcon A Toric; Device: Habitual Correction with Spectacles; Device: Habitual Correction with Contact Lenses
Sponsors: Vistakon; Vistakon; Visioncare Research Ltd.
Completed - verified August 2011 - Condition: ADHD
Interventions: Drug: SPD544; Drug: Methylphenidate hydrochloride
Sponsors: Shire Development LLC; Shire Development LLC
Completed - verified August 2011 - Condition: Anemia, Sickle Cell
Intervention: Drug: Prasugrel
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Daiichi Sankyo Co., Ltd.
Completed - verified January 2012 - Condition: Charcot Marie Tooth Disease
Intervention:
Sponsors: Wayne State University; Wayne State University; National Institute of Neurological Disorders and Stroke (NINDS); Muscular Dystrophy Association; National Hospital of Neurology and Neurosurgery, Queens Square, London, UK; The Children's Hospital at Westmead; University of Rochester; University of Miami; University of Pennsylvania; Childrens Hospital of Philadelphia; C. Besta Neurological Institute; Johns Hopkins University; University of Washington
Recruiting - verified October 2011 - Conditions: Charcot-Marie-Tooth Disease, Type Ia (Disorder); HMSN
Intervention:
Sponsors: Wayne State University; Wayne State University; National Institute of Neurological Disorders and Stroke (NINDS); Muscular Dystrophy Association; University of Rochester; University of Pennsylvania; National Hospital for Neurology and Neurosurgery; The Childrens Hospital of Westmead; Children's Hospital of Philadelphia; University of Miami; Johns Hopkins University; University of Washington
Recruiting - verified October 2011 - Condition: Smoking Cessation
Intervention: Other: Respiragene test
Sponsors: University of Surrey; University of Surrey; Lab 21, Cambridge; NHS Research and Development
Recruiting - verified March 2012 - Condition: Myositis
Intervention: Procedure: Venepuncture
Sponsors: Salford Royal NHS Foundation Trust; Salford Royal NHS Foundation Trust
Recruiting - verified September 2011 - Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster Vaccine GSK1437173A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster Vaccine GSK1437173A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Conditions: Healthy Volunteers; Safety; Tolerability
Interventions: Drug: AZD9819; Drug: AZD9819; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Completed - verified November 2011 - Condition: Healthy
Intervention: Other: Saliva sample collection
Sponsors: Institute of Food Research; Institute of Food Research; GlaxoSmithKline
Active, not recruiting - verified March 2012 - Condition: Mental Disorders
Intervention:
Sponsors: University of Bristol; University of Bristol; North Bristol NHS Trust
Active, not recruiting - verified August 2011 - Condition: Bronchiolitis
Intervention:
Sponsors: Imperial College London; Imperial College London
Suspended - verified April 2012 - Conditions: Depressive Disorder and Anxiety Disorders; Depressive Disorder
Intervention: Drug: GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011 - Condition: HIV-1 Infections
Interventions: Biological: ChAdV63.HIVconsv low dose.; Biological: ChAdV63.HIVconsv high dose.; Biological: pSG2.HIVconsv; Biological: MVA.HIVconsv; Other: Placebo
Sponsors: University of Oxford; University of Oxford
Recruiting - verified February 2012 - Condition: Irritable Bowel Syndrome
Interventions: Drug: TC-6499-12; Drug: Placebo comparator
Sponsors: Targacept Inc.; Targacept Inc.
Completed - verified December 2011 - Condition: HIV
Interventions: Other: Questionnaire; Other: Focus Group Discussion; Other: HIV test (serum or salivary); Other: Semi-structured telephone interview
Sponsors: Chelsea and Westminster NHS Foundation Trust; Chelsea and Westminster NHS Foundation Trust; Department of Health, Taiwan; Health Protection Agency, United Kingdom; Homerton University Hospital NHS Foundation Trust; King's College Hospital NHS Trust; Hammersmith and Fulham Primary Care Trust
Completed - verified May 2010 - Condition: Parkinson Disease
Intervention:
Sponsors: Michael J. Fox Foundation for Parkinson's Research; Michael J. Fox Foundation for Parkinson's Research; Institute for Neurodegenerative Disorders
Recruiting - verified July 2011 - Condition: Wheezing
Interventions: Drug: Mannitol; Drug: Montelukast
Sponsors: Queen Mary University of London; Queen Mary University of London; University of Aberdeen; University of Leicester
Recruiting - verified July 2011 - Conditions: Macrosomia; Low Birth Weight; Premature Birth; Childhood Obesity; Poverty
Intervention:
Sponsors: Swansea University; Swansea University; Cardiff University
Active, not recruiting - verified June 2010 - Condition: Cognition Disorders
Interventions: Drug: SLV354 capsules; Drug: SLV354 capsules; Drug: SLV354 capsules; Drug: SLV354 capsules; Drug: SLV354 capsules; Drug: SLV354 capsules; Drug: SLV354 capsules; Drug: SLV354 capsules; Drug: Placebo capsules; Drug: SLV354 capsules; Drug: SLV354 capsules; Drug: SLV354 capsules; Drug: SLV354 capsules; Drug: Placebo capsules
Sponsors: Abbott; Abbott; Quintiles
Terminated - verified August 2011 - Condition: Invasive Meningococcal Disease
Interventions: Biological: Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine; Biological: Routine schedule immunisations except monovalent MenC vaccine
Sponsors: University of Oxford; University of Oxford; Oxford University Hospitals NHS Trust; GlaxoSmithKline
Recruiting - verified July 2011 - Conditions: Overweight; Obese
Interventions: Drug: AZD7687; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Completed - verified January 2012 - Condition: Cognition
Interventions: Drug: Solifenacin; Drug: Oxybutynin; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Completed - verified December 2011 - Condition: Generalized Anxiety Disorder
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Cardiovascular Disease
Interventions: Dietary Supplement: Diet and Vascular Health; Dietary Supplement: Diet and Vascular Health; Dietary Supplement: Diet and Vascular Health Study
Sponsors: Institute of Food Research; Institute of Food Research; Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK); University of East Anglia
Active, not recruiting - verified June 2011 - Condition: Metabolism and Clearance of Cyanidin 3 Glucoside
Intervention: Dietary Supplement: Cyanidin 3 glucoside
Sponsors: University of East Anglia; University of East Anglia; Institute of Food Research
Completed - verified October 2011 - Conditions: AIDS/HIV PROBLEM; Sexually Transmitted Diseases
Intervention: Behavioral: Financial incentive through lotteries
Sponsors: Bocconi University; Bocconi University; World Bank
Active, not recruiting - verified May 2012 - Condition: Healthy Volunteer
Interventions: Device: Marketed nasal strip; Device: NexGen AB 2R11; Device: NexGen JB Organic PET/PE
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012 - Conditions: Ischemic Heart Disease; Transient Ischemic Attack; Stroke; Peripheral Vascular Disease
Interventions: Dietary Supplement: Ateronon; Dietary Supplement: Placebo
Sponsors: Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge Theranostics Ltd
Recruiting - verified May 2012 - Condition: Contraception
Interventions: Drug: ellaOne® (ulipristal acetate); Drug: ellaOne® (ulipristal acetate)
Sponsors: HRA Pharma; HRA Pharma
Recruiting - verified March 2012 - Conditions: Vascular Disease; Heart Disease
Interventions: Drug: Urocortin 2, Urocortin 3; Drug: Saline placebo
Sponsors: University of Edinburgh; University of Edinburgh; NHS Lothian
Suspended - verified May 2012 - Conditions: Vascular Disease; Heart Disease
Interventions: Drug: NO clamp; Drug: Saline; Drug: Fluconazole; Drug: Aspirin; Drug: Combined
Sponsors: University of Edinburgh; University of Edinburgh; NHS Lothian
Completed - verified May 2012 - Condition: Dysphoria
Interventions: Drug: Escitalopram; Drug: Placebo
Sponsors: University of Oxford; University of Oxford; P1vital Limited; University of Manchester; Institute of Psychiatry, London
Completed - verified June 2011 - Condition: Lip Enhancement
Intervention: Device: hyaluronic acid gel
Sponsors: Allergan Medical; Allergan Medical
Active, not recruiting - verified December 2011 - Condition: Cardiovascular Disease
Interventions: Dietary Supplement: Dark chocolate enriched in flavan-3-ols and procyanidins; Dietary Supplement: Standard dark chocolate; Dietary Supplement: White chocolate
Sponsors: University of Aberdeen; University of Aberdeen; Rural and Environment Research and Analysis Directorate (RERAD, UK); Biotechnology and Biological Sciences Research Council (BBSRC, UK); Natraceutical Industrial S.L.U., Valencia, Spain
Completed - verified April 2012 - Condition: Hepatitis C
Interventions: Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut ; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut
Sponsors: Okairos; Okairos; University of Oxford
Recruiting - verified October 2011 - Conditions: Fluid Overload; Water Electrolyte Imbalance; Acid Base Imbalance
Interventions: Drug: Crystalloid; Drug: Colloid
Sponsors: University of Nottingham; University of Nottingham
Completed - verified May 2011 - Condition: Eyelid Diseases
Intervention: Device: LT2420
Sponsors: Laboratoires Thea; Laboratoires Thea
Completed - verified January 2012 - Condition: Stress
Intervention:
Sponsors: SPD Development Company Limited; SPD Development Company Limited
Completed - verified September 2011 - Condition: Oral Contraceptive
Interventions: Drug: EE20/DRSP (YAZ, BAY86-5300); Drug: Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)
Sponsors: Bayer; Bayer
Completed - verified November 2011 - Condition: Breast Cancer Mortality
Intervention: Other: Invitation for breast screening
Sponsors: University of Oxford; University of Oxford; Department of Health, United Kingdom
Enrolling by invitation - verified June 2011 - Condition: Colorectal Cancer
Intervention:
Sponsors: Newcastle University; Newcastle University; Northumbria Healthcare NHS Foundation Trust
Active, not recruiting - verified October 2011 - Conditions: Attention; Memory; Mood; Mental Fatigue
Intervention:
Sponsors: Northumbria University; Northumbria University
Completed - verified August 2011 - Condition: Hepatitis C
Interventions: Biological: Ad6NSmut; AdCh3NSmut; Biological: Ad6NSmut; AdCh3NSmut; Biological: Ad6NSmut; AdCh3NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: Ad6NSmut; AdCh3NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut
Sponsors: Okairos; Okairos; University of Oxford
Completed - verified October 2011 - Condition: Ischaemia-reperfusion (IR) Injury
Interventions: Drug: C-type natriuretic peptide (CNP); Drug: Saline; Drug: Acetylcholine
Sponsors: Queen Mary University of London; Queen Mary University of London; University College, London
Not yet recruiting - verified May 2012 - Condition: Depressive Disorder and Anxiety Disorders
Interventions: Drug: Citalopram; Drug: GSK424887; Drug: Plactebo To Match
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified May 2012 - Condition: Influenza
Intervention: Dietary Supplement: Prebiotic and probiotic mix
Sponsors: University of Reading; University of Reading
Active, not recruiting - verified July 2011 - Condition: Colorectal Cancer
Interventions: Drug: Eicosapentaenoic acid free fatty acid; Drug: Placebo
Sponsors: University of Leeds; University of Leeds
Completed - verified October 2011 - Condition: Depressive Disorder and Anxiety Disorders
Interventions: Drug: GSK206136; Drug: PLACEBO; Radiation: PET
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified May 2012 - Condition: Premature Ejaculation
Interventions: Drug: Intervention A; Drug: Intervention B; Drug: Intervention C; Drug: Intervention D; Drug: Intervention E
Sponsors: Shionogi Inc.; Shionogi; Bio-Kinetic Europe Ltd; Bioclin Research Laboratories; Omnicare Clinical Research
Completed - verified July 2011 - Conditions: Major Depressive Disorder; Healthy Volunteers
Intervention: Drug: Duloxetine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Myopathy
Intervention:
Sponsors: University of Nottingham; University of Nottingham; The Dunhill Medical Trust
Recruiting - verified October 2011 - Condition: Depression
Interventions: Drug: AZD6765; Drug: Ketamine; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca; University of Manchester; University of Oxford
Completed - verified December 2011 - Condition: Squamous Cell Carcinoma of the Head and Neck Cancer
Interventions: Drug: Cetuximab in combination with EMD 1201081; Drug: Cetuximab alone
Sponsors: EMD Serono; EMD Serono
Active, not recruiting - verified January 2012 - Condition: Traveler's Diarrhea
Interventions: Biological: TD Vaccine System; Biological: TD Vaccine System
Sponsors: Intercell USA, Inc.; Intercell USA, Inc.
Completed - verified January 2012 - Conditions: Dental Caries; Oral Microbial Colonization
Interventions: Dietary Supplement: Xylitol consumption; Behavioral: Childsmile preventative programme
Sponsors: NHS Fife; NHS Fife; University of Turku
Active, not recruiting - verified December 2009 - Conditions: Failed Back Surgery Syndrome; Leg Pain; Back Pain; Spinal Cord Stimulation
Interventions: Device: Precision Spinal Cord Stimulation; Procedure: Back Surgery
Sponsors: Boston Scientific Corporation; Boston Scientific Corporation
Recruiting - verified March 2012 - Condition: Bowel Disease, Inflammatory
Intervention: Drug: GSK1070806
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2011 - Conditions: Substance Dependence; Alcoholism; Compulsive Disorder
Interventions: Drug: GSK618334 Low Dose; Drug: GSK618334 PET subjects; Drug: GSK618334 Medium Dose; Drug: GSK618334 High Dose
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: SRT2104
Sponsors: GlaxoSmithKline; Sirtris, a GSK Company; GlaxoSmithKline
Completed - verified December 2011 - Condition: Skin Cancer
Interventions: Dietary Supplement: Omega-3 PUFA; Dietary Supplement: Gelatine
Sponsors: University of Manchester; University of Manchester
Completed - verified August 2011 - Condition: Skin Cancer
Interventions: Dietary Supplement: Green tea + vitamin C high dose; Dietary Supplement: Placebo capsule
Sponsors: University of Manchester; University of Manchester; University of Leeds; University of Bradford
Recruiting - verified November 2011 - Conditions: Anaesthesia; Airway Management; Videolaryngoscopy
Interventions: Device: Macintosh Laryngoscope; Device: Pentax AWS Videolaryngoscope
Sponsors: NHS Grampian; NHS Grampian; Research and Development Department, NHS Grampian; University of Aberdeen
Not yet recruiting - verified December 2011 - Condition: Meningococcal Disease
Intervention: Biological: Serogroup B meningococcal vaccine
Sponsors: Novartis; Novartis Vaccines
Active, not recruiting - verified March 2012 - Condition: Meningococcal Disease
Intervention: Biological: Serogroup B meningococcal Vaccine
Sponsors: Novartis; Novartis Vaccines
Active, not recruiting - verified March 2012 - Conditions: Intrapartum Fetal Monitoring; Pregnancy
Interventions: Drug: Dinoprostone; Device: Monica AN 24
Sponsors: Liverpool Women's NHS Foundation Trust; Liverpool Women's NHS Foundation Trust; University of Liverpool
Completed - verified November 2011 - Condition: Infections
Interventions: Drug: echinacea; Drug: placebo
Sponsors: Bioforce AG; Bioforce AG
Completed - verified June 2011 - Condition: Renal Failure
Interventions: Procedure: Percutaneous Insertion catheter; Procedure: Open insertion Catheter
Sponsors: University of Hull; University of Hull
Not yet recruiting - verified May 2010 - Conditions: Infection; Inflammation; Allergy; Children
Intervention:
Sponsors: Imperial College London; Imperial College London
Recruiting - verified November 2011 - Conditions: QTc Evaluation; Electrocardiography
Interventions: Drug: Avelox (Moxifloxacin, BAY12-8039); Drug: Placebo
Sponsors: Bayer; Bayer
Completed - verified October 2011 - Condition: Actinic Keratosis
Intervention: Procedure: Metvix PDT
Sponsors: Galderma; Galderma
Completed - verified February 2012 - Condition: Travelers' Diarrhea
Interventions: Biological: TD Vaccine System; Biological: TD Vaccine System
Sponsors: Intercell USA, Inc.; Intercell USA, Inc.
Completed - verified March 2012 - Condition: Influenza
Intervention: Biological: MVA-NP+M1
Sponsors: University of Oxford; University of Oxford; Wellcome Trust
Completed - verified January 2011 - Condition: H1N1 Influenza Vaccination
Intervention: Other: Safety follow up
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012 - Condition: Influenza
Interventions: Drug: CS-8958; Other: Placebo
Sponsors: Biota Scientific Management Pty Ltd; Biota Scientific Management Pty Ltd; National Institute of Allergy and Infectious Diseases (NIAID)
Completed - verified October 2011 - Condition: Chronic Kidney Disease
Interventions: Other: Progressive resistance training programme; Other: Sham exercise; Other: Progressive resistance training; Other: Sham exercise
Sponsors: Bangor University; Bangor University; Betsi Cadwaladr University Health Board
Completed - verified December 2011 - Conditions: Type 2 Diabetes; Obesity
Intervention: Behavioral: 8-month group lifestyle programme
Sponsors: The Royal Bournemouth Hospital; The Royal Bournemouth Hospital
Recruiting - verified August 2011 - Condition: Insulin Resistance
Intervention: Dietary Supplement: Cocoa
Sponsors: University of Nottingham; University of Nottingham; Mars, Inc.
Completed - verified January 2012 - Condition: Pharmacokinetics
Interventions: Drug: SLV342; Drug: placebo
Sponsors: Abbott; Abbott Products; Quintiles
Terminated - verified August 2011 - Condition: HIV Infections
Interventions: Drug: Ribavirin; Drug: Raltegravir
Sponsors: Imperial College London; Imperial College London
Completed - verified November 2011 - Conditions: Cognitive Function; Mood
Interventions: Dietary Supplement: EGCG; Dietary Supplement: Placebo
Sponsors: Northumbria University; Northumbria University
Completed - verified March 2012 - Condition: Healthy
Intervention: Drug: Levetiracetam (Keppra)
Sponsors: UCB, Inc.; UCB, Inc.
Completed - verified May 2012 - Condition: Giant Cell Arteritis
Interventions: Procedure: Ultrasound of temporal and axillary arteries; Procedure: Temporal artery biopsy
Sponsors: University of Oxford; University of Oxford; University of Sheffield; Southend University Hospital; Nuffield Orthopaedic Centre NHS Trust; John Radcliffe Hospital; The Leeds Teaching Hospitals NHS Trust; University of Bristol; London School of Hygiene and Tropical Medicine; Medical Center for Rheumatology Berlin-Buch
Recruiting - verified January 2012 - Condition: Healthy
Interventions: Drug: Part 1 - AZD2423 or Placebo; Drug: Part 2 - AZD2423; Drug: Part 3 - AZD2423
Sponsors: AstraZeneca; AstraZeneca
Completed - verified June 2010 - Condition: Hypercholesterolemia
Interventions: Dietary Supplement: Wheat bran; Dietary Supplement: 3g high MW; Dietary Supplement: 4g medium MW; Dietary Supplement: 3g medium MW; Dietary Supplement: 4g low MW
Sponsors: Glycemic Index Laboratories, Inc; Glycemic Index Laboratories, Inc; CreaNutrition, AG; University of Guelph; University of Sydney; Laval University; Reading Scientific Services, Ltd.; University of Toronto; Agriculture and Agri-Food Canada
Completed - verified June 2011 - Conditions: Irritable Bowel Syndrome; Post Infective Bowel Dysfunction
Interventions: Drug: Saccharomyces Cerevisiae CNCM I-3856; Drug: placebo
Sponsors: University of Nottingham; University of Nottingham; Lesaffre International
Withdrawn - verified January 2012 - Conditions: Heart Failure; Sleep Apnea Syndromes
Intervention:
Sponsors: ResMed; ResMed; Royal Brompton & Harefield NHS Foundation Trust; Imperial College London
Completed - verified November 2011 - Condition: Healthy
Interventions: Drug: DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl); Drug: DDS-06C (650 mg acetaminophen and 75 mg tramadol); Drug: Zaldiar®; Drug: Ultracet®; Drug: Two tablets of DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl), multiple doses, under both fed and fasting conditions; Drug: Zaldiar®, multiple doses,(fed & fasting):; Drug: Ultracet®, multiple doses, (fed & fasting)
Sponsors: Labopharm Inc.; Labopharm Inc.
Completed - verified April 2012 - Condition: Idiopathic Inflammatory Myopathy
Intervention:
Sponsors: Salford Royal NHS Foundation Trust; Salford Royal NHS Foundation Trust
Recruiting - verified October 2009 - Conditions: Anesthesia; Child; Infant
Intervention:
Sponsors: University Hospitals Bristol NHS Trust; University Hospitals Bristol NHS Trust; Royal United Hospital Bath NHS Trust
Terminated - verified December 2011 - Conditions: Pain; Hyperalgesia
Interventions: Drug: ICA-105665; Drug: ibuprofen; Drug: Placebo
Sponsors: Icagen; Icagen
Completed - verified July 2011 - Conditions: Meningococcal Meningitis, Serogroup A; Meningococcal Meningitis, Serogroup B; Meningococcal Meningitis, Serogroup C; Meningococcal Meningitis, Serogroup Y; Meningococcal Meningitis, Serogroup W
Intervention: Drug: meningococcal B vaccine & meningococcal ACYW conjugate vaccine
Sponsors: Health Protection Agency, United Kingdom; Dr. Elizabeth Miller; Novartis Vaccines
Completed - verified March 2012 - Condition: HPV Infections
Interventions: Biological: Cervarix; Biological: Gardasil
Sponsors: Health Protection Agency, United Kingdom; Dr. Elizabeth Miller
Recruiting - verified March 2012 - Conditions: Meningococcal Disease; Meningococcal Meningitis
Interventions: Biological: rMenB+OMV NZ with routine vaccinations; Biological: rMenB+OMV NZ with routine vaccinations; Biological: rMenB+OMV NZ; Biological: rMenB+OMV NZ; Biological: rMenB+OMV NZ with routine vaccinations; Biological: rMenB+OMV NZ with routine vaccinations; Biological: two doses of rMenB+OMV NZ; Biological: rMenB+OMV NZ with routine vaccinations; Biological: two doses of rMenB+OMV NZ; Biological: rMenB+OMV NZ; Biological: two doses of rMenB+OMV NZ; Biological: rMenB+OMV NZ with routine vaccinations
Sponsors: Novartis; Novartis Vaccines
Completed - verified February 2012 - Condition: Influenza
Interventions: Biological: MVA-NP+M1; Biological: MVA-NP+M1; Biological: MVA-NP+M1
Sponsors: University of Oxford; University of Oxford; Wellcome Trust
Recruiting - verified June 2011 - Condition: Insomnia
Interventions: Drug: Prolonged-release melatonin; Drug: Temazepam; Drug: Zolpidem; Drug: Placebo to match melatonin, zolpidem and temazepam
Sponsors: University of Surrey; University of Surrey; H. Lundbeck A/S
Completed - verified November 2009 - Conditions: Diabetes Mellitus, Type 2; Healthy Volunteer
Intervention: Drug: 0.5g SRT2104
Sponsors: GlaxoSmithKline; Sirtris, a GSK Company; GlaxoSmithKline
Completed - verified August 2011 - Conditions: Diabetes Mellitus, Type 2; Healthy Volunteer
Interventions: Drug: 250 mg SRT2104 Suspension; Drug: Carbon-14 radio-labeled SRT2104
Sponsors: GlaxoSmithKline; Sirtris, a GSK Company; GlaxoSmithKline
Completed - verified August 2011 - Conditions: Diabetes Mellitus, Type 2; Healthy Volunteer
Interventions: Drug: SRT2104; Drug: Placebo
Sponsors: GlaxoSmithKline; Sirtris, a GSK Company; GlaxoSmithKline
Completed - verified August 2011 - Conditions: Appetite Regulation; Obesity
Interventions: Dietary Supplement: Oligofructose; Dietary Supplement: Placebo
Sponsors: Imperial College London; Imperial College London
Completed - verified December 2011 - Condition: Migraine
Intervention:
Sponsors: The City of London Migraine Clinic; The City of London Migraine Clinic; Genomics Research Centre, Griffith University, Australia
Recruiting - verified July 2011 - Condition: Malaria
Interventions: Biological: AdCh63 ME-TRAP; Biological: AdCh63 ME-TRAP; MVA ME-TRAP
Sponsors: University of Oxford; University of Oxford
Completed - verified October 2011 - Condition: Diabetic Neuropathy
Intervention:
Sponsors: Tameside Hospital NHS Foundation Trust; Tameside Hospital NHS Foundation Trust
Recruiting - verified May 2009 - Condition: Phenylketonuria
Interventions: Dietary Supplement: high oleic sunflower oil; Dietary Supplement: microalgal oil; Dietary Supplement: microalgal oil; Dietary Supplement: microalgal oil; Dietary Supplement: microalgal oil
Sponsors: Ludwig-Maximilians - University of Munich; Ludwig-Maximilians - University of Munich; European Union
Active, not recruiting - verified October 2011 - Condition: Dental Caries
Intervention: Other: Fluoride varnish
Sponsors: University of St Andrews; University of St Andrews
Recruiting - verified July 2011 - Condition: Cardiovascular Disease
Intervention: Other: Fruit and vegetable intervention
Sponsors: Queen's University, Belfast; Queen's University, Belfast
Completed - verified August 2011 - Conditions: Poliomyelitis; Diphtheria; Whooping Cough; Meningococcal Serogroup C Infections; Haemophilus Influenzae Type b Infections; Tetanus
Interventions: Biological: GSK2197870A vaccine; Biological: Prevenar™; Biological: Menitorix™; Biological: Sanofi-Pasteur's PediacelTM; Biological: Novartis' Menjugate TM; Biological: GSK Biologicals' Priorix TM; Biological: Prevenar™ or Prevenar 13™
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011 - Condition: Alzheimer's Disease
Intervention:
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Institute on Aging (NIA)
Recruiting - verified October 2011 - Condition: Laparoscopic Cholecystectomy
Intervention: Other: Succinylated gelatine, 40g/L, (Gelofusine - B Braun)
Sponsors: University of Nottingham; University of Nottingham; Sherwood Forest Hospitals NHS Foundation Trust
Completed - verified November 2011 - Condition: Asthma
Interventions: Drug: Azithromycin; Drug: Placebo
Sponsors: University of Glasgow; Euan J Cameron; University of Glasgow; NHS Greater Glasgow and Clyde
Completed - verified October 2011 - Condition: Colorectal and Ovarian Cancer Patients With Liver Metastasis
Intervention: Biological: EMD525797
Sponsors: Merck KGaA; Merck KGaA
Recruiting - verified February 2012 - Condition: Lung Cancer
Intervention: Drug: Cisplatin, Paclitaxel
Sponsors: University College, London; University College, London; Eli Lilly and Company; Cancer Research UK
Recruiting - verified January 2012 - Condition: Trachoma
Interventions: Drug: Azithromycin; Drug: Azithromycin
Sponsors: Johns Hopkins University; Johns Hopkins University; Bill and Melinda Gates Foundation
Active, not recruiting - verified March 2012 - Condition: Asthma
Intervention: Other: bronchoscopy
Sponsors: Imperial College London; Imperial College London; Asthma UK; Royal Brompton & Harefield NHS Foundation Trust
Recruiting - verified June 2011 - Condition: Meningococcal Infections
Intervention: Biological: NZ MenB OMV vaccine (NZ98/254)
Sponsors: United Bristol Healthcare NHS Trust; United Bristol Healthcare NHS Trust; University of Bristol; Health Protection Agency, United Kingdom; Novartis Vaccines; North Bristol NHS Trust
Recruiting - verified January 2010 - Conditions: Alcohol Abuse; Drug Abuse; Depression; Panic Disorder; Conduct Disorder
Intervention: Behavioral: Personality-targeted interventions
Sponsors: King's College London; King's College London; Action on Addiction
Completed - verified December 2010 - Condition: Influenza Disease
Interventions: Biological: GSK Bio's influenza vaccine GSK2186877A; Biological: Fluarix TM
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012 - Condition: Influenza
Intervention: Biological: Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009
Sponsors: Novartis; Novartis Vaccines
Completed - verified January 2012 - Conditions: Pulmonary Disease, Chronic Obstructive; Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: GSK573719
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012 - Condition: Gastroparesis
Intervention: Drug: GSK962040 oral tablets (1, 5, 10, 25 mg)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2011 - Condition: Substance Dependence
Intervention: Drug: GSK598809
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2011 - Condition: Obesity
Intervention: Drug: V24343
Sponsors: Vernalis (R&D) Ltd; Vernalis (R&D) Ltd
Completed - verified July 2011 - Condition: Meningococcal Infections
Interventions: Biological: rMenB and concomitantly routine infant vaccinations; Biological: rMenB and routine infant vaccinations; Biological: rMenB and concomitantly routine infant vaccinations; Biological: Routine infant vaccines
Sponsors: Novartis; Novartis Vaccines
Completed - verified October 2011 - Conditions: Pulmonary Disease, Chronic Obstructive; Healthy Volunteer
Interventions: Drug: GW642444; Drug: GW642444; Drug: GW642444; Drug: GW642444; Drug: GW642444; Drug: GW642444
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2011 - Condition: Osteoarthritis
Interventions: Drug: Oral Salmon Calcitonin; Drug: Oral Salmon Calcitonin (Placebo)
Sponsors: Nordic Bioscience A/S; Nordic Bioscience A/S; Novartis
Completed - verified July 2011 - Conditions: Healthy Subjects; Purpura, Thrombocytopenic, Idiopathic
Interventions: Drug: Ciprofloxacin; Drug: Eltrombopag; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified August 2011 - Conditions: Healthy; Anesthesia
Interventions: Drug: Rapydan; Drug: tetracaine gel
Sponsors: EUSA Pharma (US), Inc.; EUSA Pharma (US), Inc.
Withdrawn - verified April 2012 - Conditions: Healthy Subjects; Malaria
Intervention: Drug: GSK369796
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Medicines for Malaria Venture
Completed - verified October 2011 - Conditions: Osteoporosis; Low-energy Trauma Fracture
Interventions: Device: DXA scan of hip; Device: CT scan of hip
Sponsors: Sheffield Teaching Hospitals NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation Trust; Medical Research Council; Hologic, Inc.
Active, not recruiting - verified July 2011 - Condition: Thalassemia
Intervention:
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI); Thalassemia Clinical Research Network
Completed - verified June 2011 - Condition: Premature Ejaculation
Intervention: Drug: GSK958108
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2011 - Condition: Hernia
Intervention:
Sponsors: Ethicon, Inc.; Ethicon, Inc.
Recruiting - verified April 2012 - Conditions: Allergic Rhinitis; Rhinitis, Allergic, Seasonal
Intervention: Drug: GSK835726
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2011 - Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Drug: GW856553
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012 - Condition: Meningococcal Disease
Interventions: Other: Blood test; Other: Blood test
Sponsors: Novartis; Novartis; Novartis Vaccines
Completed - verified July 2011 - Conditions: Overweight; Obesity; Metabolic Syndrome
Interventions: Other: control diet, supported by dietary supplement twice daily; Other: high cereal fiber diet, supported by dietary supplement twice daily; Other: high protein diet, supported by dietary supplement twice daily; Other: diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily
Sponsors: German Institute of Human Nutrition; German Institute of Human Nutrition; German Federal Ministry of Education and Research; University of Warwick; University Hospitals Coventry and Warwickshire NHS Trust; Medical University of Vienna; Heinrich-Heine University, Duesseldorf; University Hospital Tuebingen; Charite University, Berlin, Germany; Klinikum Ernst von Bergmann Potsdam; Institute for Cereal Processing Potsdam-Rehbruecke
Completed - verified April 2012 - Condition: Healthy
Intervention: Drug: [14C]-bilastine
Sponsors: Faes Farma, S.A.; Faes Farma, S.A.; Charles River Clinical Services Edinburgh Ltd and CR Laboratories Preclinical Services Ltd; MDS Pharma Services Switzerland AG
Completed - verified April 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Drug: A single 10mg (50 μCi) oral dose of [14C]SB-681323
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012 - Condition: Influenza
Interventions: Drug: oseltamivir; Drug: oseltamivir; Other: Alternative Control
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Influenza
Interventions: Biological: GlaxoSmithKline Biologicals' influenza vaccine GSK576389A; Biological: Fluarix
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2011 - Condition: Breast Cancer
Interventions: Genetic: gene expression analysis; Genetic: molecular diagnostic method; Genetic: polymorphism analysis; Genetic: protein expression analysis; Other: medical chart review; Other: questionnaire administration
Sponsors: National Cancer Institute (NCI); National Cancer Research Network
Recruiting - verified September 2007 - Condition: Influenza
Intervention: Biological: Surface antigen inactivated influenza vaccine
Sponsors: Novartis; Novartis Vaccines
Completed - verified November 2011 - Condition: Locally Recurrent and Metastatic Breast Cancer
Interventions: Drug: AMG 386 Placebo; Drug: AMG 386; Drug: Bevacizumab; Drug: AMG 386; Drug: AMG 386; Drug: Paclitaxel
Sponsors: Amgen; Amgen
Active, not recruiting - verified September 2011 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Pfizer
Completed - verified November 2011 - Condition: Bipolar Disorder
Interventions: Drug: GSK drug; Other: Placebo; Other: Lamictal
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2011 - Condition: Gastroesophageal Reflux
Intervention:
Sponsors: Guy's and St Thomas' NHS Foundation Trust; Guy's and St Thomas' NHS Foundation Trust
Completed - verified June 2011 - Condition: Prophylaxis of Avian Influenza Vaccine
Intervention: Biological: Fluad H5N1 Pandemic Influenza Vaccine
Sponsors: Novartis; Novartis Vaccines
Completed - verified February 2012 - Condition: Prophylaxis H. Influenzae Type b and Meningococcal Serogroup C Diseases
Interventions: Biological: Menitorix; Biological: Infanrix IPV
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012 - Conditions: Substance Dependence; Compulsive Behavior
Intervention: Drug: GSK598809/Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2011 - Condition: Meningococcal Disease
Intervention: Biological: Serogroup B meningococcal Vaccine
Sponsors: Novartis; Novartis Vaccines
Completed - verified January 2012 - Conditions: Brain Tumor; Glioma
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Healthy
Intervention: Drug: RSV604
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified November 2011 - Conditions: Schizophrenia; Healthy Subjects
Interventions: Drug: SB773812; Drug: Ketoconazole
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2011 - Condition: Obstetric Labour, Premature
Interventions: Drug: GSK221149A; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012 - Condition: Healthy
Intervention: Biological: Serogroup B meningococcal Vaccine
Sponsors: Novartis; Novartis Vaccines
Completed - verified January 2012 - Condition: Insomnia
Interventions: Drug: Eszopiclone; Drug: Placebo
Sponsors: Sunovion; Sunovion
Completed - verified February 2012 - Condition: Arthritis, Rheumatoid
Intervention: Drug: GW274150
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012 - Conditions: Coronary Artery Disease; Coronary Artery Stenosis
Intervention: Device: Coronary stent implantation
Sponsors: OrbusNeich; OrbusNeich
Active, not recruiting - verified August 2011 - Conditions: Alcohol Abuse; Drug Abuse; Depression; Panic Disorder; Conduct Disorder
Intervention: Behavioral: PRE-Venture: Personality Risk Education
Sponsors: King's College London; King's College London; Action on Addiction
Completed - verified February 2006 - Condition: Influenza
Interventions: Biological: Candidate Influenza Vaccine GSK1247446A - 3 different formulations; Biological: Fluarix TM
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011 - Condition: Healthy
Interventions: Drug: Propofol; Device: Patient maintained sedation
Sponsors: University of Glasgow; Sonia Allam; NHS Greater Glasgow and Clyde
Completed - verified February 2012 - Condition: Prevention of Meningococcal Infection
Intervention: Biological: Meningococcal C conjugate vaccine
Sponsors: Novartis; Novartis Vaccines
Completed - verified November 2011 - Condition: Prophylaxis for HPV Infections and Associated Cervical Neoplasia
Interventions: Biological: Cervarix; Biological: Placebo control
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified February 2012 - Conditions: Pulmonary Disease, Chronic Obstructive; Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Other: Novel endpoint determination
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012 - Condition: Human Immunodeficiency Virus Infections
Interventions: Drug: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs); Drug: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs); Drug: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs); Drug: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)
Sponsors: Abbott; Abbott
Completed - verified February 2012 - Conditions: Haemophilus Influenzae Type b Disease; Meningococcal Serogroup Diseases
Intervention: Biological: Haemophilus influenzae type b- and meningococcal (vaccine)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011 - Condition: Herpes Simplex
Interventions: Biological: GSK208141; Biological: HavrixTM (investigational formulation); Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012 - Condition: Influenza
Interventions: Biological: Cold-adapted influenza vaccine trivalent (CAIV-T); Biological: Placebo
Sponsors: MedImmune LLC; MedImmune LLC; Wyeth is now a wholly owned subsidiary of Pfizer
Completed - verified February 2012 - Conditions: Pneumococcal Infections; Meningococcal Infections
Interventions: Biological: menjugate; Biological: Men C conjugate vaccine; Biological: Men C conjugate; Biological: Men C Conjugate; Biological: Men C conjugate; Biological: Men C conjugate
Sponsors: Health Protection Agency, United Kingdom; Health Protection Agency, United Kingdom
Completed - verified March 2012 - Condition: Toxemia
Intervention: Behavioral: preeclampsia
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified March 2012 - Conditions: Cerebellar Ataxias; Spastic Paraplegias
Intervention:
Sponsors: Institut National de la Santé Et de la Recherche Médicale, France; Institut National de la Santé Et de la Recherche Médicale, France; Institut des Maladies Rares; Agence Nationale de la Recherche
Recruiting - verified March 2012 - Conditions: Human Papillomavirus (HPV) Infection; Cervical Neoplasia
Interventions: Biological: Cervarix™; Biological: Havrix™-based investigational formulation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012 - Conditions: Thrombocytopenia; Thrombocytopaenia
Interventions: Drug: SB497115; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2011 - Condition: Diabetes Mellitus, Type 1
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Drug: anastrozole
Sponsors: Queen Mary University of London; Jill Knox
Active, not recruiting - verified April 2012
 |
Join Clinical Trials for Healthy Volunteers in Isle of Man |
